Journal of Clinical Psychiatry

Subject Index to Volume 51: January 1990 Through December 1990

Academic Highlights
Current and potential uses of lithium. Sept 392–399
Acquired Immunodeficiency Syndrome
Clonazepam treatment of acute mania in an AIDS patient [letter]. Budman, May 212
Adjustment Disorder
Anxiety and adjustment disorder: a treatment approach. Schatzberg, Nov suppl 20–24
Psychosocial stressors and adjustment disorder: Van Gogh's life chart illustrates stress and disease. Rahe, Nov suppl 13–19
Adolescents
Diagnosis and treatment of adolescent anxiety disorders. Biederman, May suppl 20–26. Correction, Oct 440
DSM-III-R classification of murderous youth: help or hindrance? Myers, June 239–242
Epidemiologic study of Tourette's syndrome in a single school district. Comings, Nov 463–469
Affective Disorders see Mood Disorders
Aggression see Violence
Agoraphobia
Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia. Mavissakalian, May 184–188
Akathisia
Akathisia and fluoxetine [letter]. Maany; Lipinski reply, May 210–212
Fluoxetine and stuttering [letter]. Friedman; Guthrie reply, July 310
Fluoxetine-induced akathisia in male OCD patients [letter]. Friedman, May 212
Is relapse a justification for the use of high-dose antipsychotics [letter]? Cohen; McCormick reply, Nov 486–487
Alcohol and Alcoholism
Panic disorder and cocaine abuse in alcoholics [letter]. Yates, Oct 440
Shared features of neuroleptic malignant syndrome and alcohol abuse complications [letter]. Krystal, Dec 523
Subjective feelings of anxiety in young men after ethanol and diazepam infusions. Monteiro, Jan 12–16
Alexithymia
Alexithymia among Vietnam veterans with posttraumatic stress disorder. Hyer, June 243–247
Alprazolam
Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Udelman, Sept suppl 46–50
Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Braun, June 236–238
Emerging uses for high-potency benzodiazepines in psychotic disorders. Patterson, May suppl 41–46
Managing long-term therapy for panic disorder. Burrows, Nov suppl 9–12
Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. Risse, May 206–209
Withdrawal from alprazolam dependency using clonazepam: clinical observations. Patterson, May suppl 47–49
Alzheimer's Disease see also Dementia
Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. Gleason, Mar 115–118
Drug preferences of alcoholic polydrug abusers with and without panic. Jensen, May 189–191
Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial. Jenike, Jan 3–7
Treatment of psychotic symptoms in Alzheimer's patients [letter]. Ankenman; Schneider reply, Oct 437–438
Amitriptyline
Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled multicenter comparison study in outpatients with major depression. Reimherr, Dec suppl B 18–27
Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. Cohn, Dec suppl B 28–33
Drug utilization review of prescribing patterns for trazodone versus amitriptyline. Bryant, Sept suppl 27–29
Tinnitus associated with amitriptyline [letter]. Feder, Feb 85–86
Anger
Anticholinergic antidepressants decrease marital hostility [letter]. Sabelli, Mar 127–128
Serotonergic activity and hostility [letter]. Everett; Sabelli reply, Oct 438–439
Anorexia Nervosa
Fluoxetine treatment of anorexia nervosa: an open clinical trial. Gwirtsman, Sept 378–382
Anticholinergic Agents
Anticholinergic antidepressants decrease marital hostility [letter]. Sabelli, Mar 127–128
Serotonergic activity and hostility [letter]. Everett; Sabelli reply, Oct 438–439
Anticoagulants
Anticoagulant therapy for dementia [letter]. Walsh, Dec 522
Antidepressants see Antidepressive Agents
Antidepressants, Tricyclic
Pathophysiology of tricyclic-induced sweating [letter]. Leeman, June 258–259
Patients with frequent sleep panic: clinical findings and response to medication treatment. Mellman, Dec 513–516
Antidepressive Agents see also specific drugs
Anticholinergic antidepressants decrease marital hostility [letter]. Sabelli, Mar 127–128
Antidepressant drug side effects. Cole, Jan suppl 21–26
Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled multicenter comparison study in outpatients with major depression. Reimherr, Dec suppl B 18–27
Antidepressant tachyphylaxis [letter]. Lieb, Jan 36
Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. Price, Apr suppl 44–50
Combining antidepressants and psychotherapy: rationale and strategies. Perry, Jan suppl 16–20
Cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a medicaid population. McCombs, June suppl 60–69
Maintenance treatment with antidepressants in panic disorder. Noyes Jr, Dec suppl A 24–30
Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants. Clary, June 226–231
Role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. Blier, Apr suppl 14–20
Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. Austin, Aug 344–345
What are "cyclic" antidepressants [letter]? van Kempen; Salzman reply, Aug 348–349
Antipsychotic Agents see Tranquilizing Agents, Major
Anxiety
Anxiety and adjustment disorder: a treatment approach. Schatzberg, Nov suppl 20–24
Anxiety and mood disorders in medically ill patients. Wise, Jan suppl 27–32
Anxiety disorders during acute bereavement: risk and risk factors. Jacobs, July 269–274
Anxiety in the elderly: treatment strategies. Salzman, Oct suppl 18–21
Buspirone therapy for elderly patients with anxiety or depressive neurosis [letter]. Böhm, July 309
Chronic anxiety: deciding the length of treatment. Gorman, Jan suppl 11–15
Comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. Clayton, Nov suppl 35–39
Comorbidity of anxiety and depression in general medical patients: a longitudinal study. Zung, June suppl 77–80
Comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. Murphy, Apr suppl 53–58
Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Udelman, Sept suppl 46–50
Diagnosis and treatment of adolescent anxiety disorders. Biederman, May suppl 20–26. Correction, Oct 440
Discussant presentation: serotonin partial agonists in the treatment of depression. Dimitriou, Sept suppl 65–66
Double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. Strand, Sept suppl 40–45
Effect of long-term imipramine treatment on carbon dioxide-induced anxiety in panic disorder patients. Woods, Dec 505–507
Generalized anxiety disorder: new concepts and psychopharmacologic therapies. Dubovsky, Jan suppl 3–10
High anxiety in children. Graae, May suppl 18–19
Introduction. Anxiety: the burden of illness. Pasnau, Nov Suppl 3–4
Practical considerations in the pharmacologic treatment of depression and anxiety in the elderly. Salzman, Jan suppl 40–43
Subjective feelings of anxiety in young men after ethanol and diazepam infusions. Monteiro, Jan 12–16
Targeting treatment in patients with mixed symptoms of anxiety and depression. Fawcett, Nov suppl 40–43
Treatment of anxiety disorder in patients with mood disorders. Coplan, Oct suppl 9–13
Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. Petracca, Sept suppl 31–39
Understanding and treating depression in anxious patients. Dubovsky, Oct suppl 3–8
Attention Deficit Disorder
Retrospective assessment of DSM-III attention deficit disorder in nonreferred individuals. Biederman, Mar 102–106
Attention-Deficit Hyperactivity Disorder
Controlled family history study of Tourette's syndrome, I: attention-deficit hyperactivity disorder and learning disorders. Comings, July 275–280

Behavior Therapy
Long-term outcome for patients with panic disorder treated with cognitive-behavioral therapy. Barlow, Dec suppl A 17–23
Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia. Mavissakalian, May 184–188
Treating the anxiety: therapeutic options in obsessive compulsive disorder. Greist, Nov suppl 29–34
Benzodiazepines see also specific drugs
Cocaine augments peripheral benzodiazepine binding in humans. Chesley, Oct 404–406
Continuation treatment of panic disorder with high-potency benzodiazepines. Davidson, Dec suppl A 31–37
Emerging uses for high-potency benzodiazepines in psychotic disorders. Bodkin, May suppl 41–46
High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience. Tesar, May suppl 4–10
Introduction. High-potency benzodiazepines: emerging uses in psychiatry. Rosenbaum, May suppl 3
Long-term management of panic disorder. Pollack, May suppl 11–13
Subjective feelings of anxiety in young men after ethanol and diazepam infusions. Monteiro, Jan 12–16
Benzoylecgonine
Prolonged detection period for cocaine and metabolite [letter]. Weddington, Aug 347
Prolonged presence of metabolite in urine after compulsive cocaine use. Burke, Apr 145–148
Bipolar Disorder
Bipolar disorder and Crohn's disease. Holroyd, Oct 407–409
Bupropion as a promising approach to rapid cycling bipolar II patients. Haykal, Nov 450–455
Clonazepam and bipolar affective disorder [letter]. Bansil; Sachs reply, Dec 522–523
Introduction. Recent advances in bipolar and obsessive compulsive disorders: nature and treatment. Greist, Aug suppl 3
Lithium-induced worsening of wintertime depression in a bipolar patient [letter]. Dilsaver, Aug 347–348
Lithium treatment during pregnancy, delivery, and lactation: an update. Schou, Oct 410–413
Non-lithium treatment for bipolar disorder. Post, Aug suppl 9–16
Problems in diagnosing bipolar disorder in catatonic patients. Fein, May 203–205
Schizophrenic individuals with bipolar first-degree relatives: analysis of two pedigrees. Pope Jr, Mar 97–101
Treatment of psychotic symptoms in Alzheimer's patients [letter]. Ankenman; Schneider reply, Oct 437–438
Use of clonazepam for bipolar affective disorder. Sachs, May suppl 31–34
Valproate use in the older manic patient. McFarland, Nov 479–481
Blood Levels
Excretion of fluoxetine in human breast milk [letter]. Isenberg, Apr 169
Hyperamylasemia and binge-purge episodes [letter]. Walsh; Gwirtsman reply, Mar 128–129
Imipramine equivalents [letter]. Kantor; Weilburg reply, June 257
Relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. Mazure, Aug 330–334
Books Reviewed
Amantea C: *The Lourdes of Arizona, With an Interview by R. D. Laing*. Karasu, Apr 170
Andersen AE (ed): *Males With Eating Disorders*. Larocca, Sept 390–391
Andolfi M, Angelo C, De Nichilo M (eds): *The Myth of Atlas: Families and the Therapeutic Story*. Millsap, Oct 441–442
Ban TA, Lehmann HE (eds): *Diagnosis and Treatment of Old Age Dementias*. Flint, Feb 88–89
Barker P: *Basic Child Psychiatry, 5th ed*. Adam, Jan 41
Bar-Levav R: *Thinking in the Shadow of Feelings: A New Understanding of the Hidden Forces that Shape Individuals and Societies*. Larocca, May 214
Benedek EP, Cornell DG (eds): *Juvenile Homicide*. Dos Santos, May 216
Bienenfeld D (ed): *Verwoerdt's Clinical Geropsychiatry, 3rd ed*. Blazer, Oct 441
Bowlby J: *A Secure Base: Parent-Child Attachment and Healthy Human Development*. Kourany, Feb 89
Brown JW (ed): *Agnosia and Apraxia: Selected Papers of Liepmann, Lange, and Potzl*. Jones and Long, Jan 40–41
Burton SW, Akiskal HS (eds): *Dysthymic Disorder*. Deltito, Sept 391
Cath SH, Gurwitt A, Gunsberg L (eds): *Fathers and Their Families*. Huntley, Aug 351
Chaudron CD, Wilkinson DA (eds): *Theories on Alcoholism*. Martin, July 312
Chessick RD: *The Technique and Practice of Listening in Intensive Psychotherapy*. Khantzian, May 214
Ciliska D: *Beyond Dieting: Psychoeducational Interventions for Chronically Obese Women: A Non-Dieting Approach*. Larocca, Dec 527
Cussack O: *Pets and Mental Health*. Rosenthal, Mar 131
Davison K, Kerr A (eds): *Contemporary Themes in Psychiatry: A Tribute to Sir Martin Roth*. Alarcon, Nov 488
Dickstein LJ, Nadelson CC (eds): *Family Violence: Emerging Issues of a National Crisis*. Pugh, Jan 40
Dupont J (ed); Bálint M, Jackson NZ (trans): *The Clinical Diary of Sándor Ferenczi*. Moussong-Kovács, July 312–313
Everstine DS, Everstine L: *Sexual Trauma in Children and Adolescents: Dynamics and Treatment*. Bernet, Jan 41
Frank BD, Kluft RP (eds): *Treatment of Victims of Sexual Abuse*. Albrecht, Jan 41
Glick ID, Clarkin JF, Kessler DR: *Marital and Family Therapy, 3rd ed*. Keitner, Sept 390
Havens L: *A Safe Place: Laying the Groundwork of Psychotherapy*. Goldstein, May 215–216
Hsu LKG: *Eating Disorders*. Larocca, Sept 390–391
Hughes S: *Ryan: A Mother's Story of Her Hyperactive/Tourette Syndrome Child*. Thaggard, Nov 489
Juengst ET, Koenig BA (eds): *The Meaning of AIDS: Implications for Medical Science, Clinical Practice, and Public Health Policy*. Billings, Apr 171
Kaplan HS: *How to Overcome Premature Ejaculation*. Levine, Mar 130
Kemberg OF, Selzer MA, Koenigsberg HW, Carr AC, Appelbaum AH: *Psychodynamic Psychotherapy of Borderline Patients*. Links, June 261–262
Kulka RA, Schlenger WE, Fairbank JA, et al: *Trauma and the Vietnam War Generation: Report of Findings From the National Vietnam Veterans Readjustment Study, Vols. 1 and 2*. Kuhne, Nov 488–489
Lask B, Fosson A: *Childhood Illness: The Psychosomatic Approach*. Kontras, July 312
Lefley HP, Johnson DL (eds): *Families as Allies in Treatment of the Mentally Ill*. Keitner, Dec 526
Lewis JM: *The Birth of a Family: An Empirical Inquiry*. Stein, June 262
Marsella AJ, Hirschfeld RMA, Katz MM (eds): *The Measurement of Depression*. Alarcon, Feb 87
Murphy LR, Schoenborn TF (eds): *Stress Management in Work Settings*. Rosenthal, May 216
Piran N, Kaplan AS (eds): *A Day Hospital Group Treatment Program for Anorexia Nervosa and Bulimia Nervosa*. Larocca, Sept 390–391
Pirog-Good MA, Stets JE (eds): *Violence in Dating Relationships: Emerging Social Issues*. Heiman, Mar 131–132
Pressman B, Cameron G, Rothery M (eds): *Intervening With Assaulted Women: Current Theory, Research, and Practice*. Surawicz, Oct 442
Robins LN, Barrett JE (eds): *The Validity of Psychiatric Diagnosis*. Alarcon, Apr 170–171
Ross CA: *Multiple Personality Disorder: Diagnosis, Clinical Features, and Treatment*. Goldstein, July 313
Roth N: *The Psychiatry of Writing a Will*. Tanay, Aug 351
Rothblum ED, Cole E (eds): *Lesbianism: Affirming Nontraditional Roles*. Surawicz, Nov 489
Sameroff AJ, Emde RN (eds): *Relationship Disturbances In Early Childhood: A Developmental Approach*. Paulauskas, Mar 132
Seeman MV, Greben SE (eds): *Office Treatment of Schizophrenia*. Gold, Dec 526–527
Spitzer RL, Gibbon M, Skodol AE, et al. (eds): *DSM-III-R Casebook*. Rosenzweig and Gruenberg, Mar 130
Tardiff K: *Assessment and Management of Violent Patients*. Penna, Oct 442
Unkefer RF (ed): *Music Therapy in the Treatment of Adults With Mental Disorders: Theoretical Bases and Clinical Interventions*. Frosch, Dec 527
Vaux A: *Social Support: Theory, Research and Intervention*. Scott, Feb 87–88
Vinogradov S, Yalom ID: *A Concise Guide to Group Psychotherapy*. Khanna, June 262
Waldinger RJ, Gunderson JG: *Effective Psychotherapy With Borderline Patients*. Kroll, May 214–215
Weil JL: *Instinctual Stimulation of Children: From Common Practice to Child Abuse, vols. 1 and 2*. Bernet, Mar 130–131
Wills C: *The Wisdom of the Genes: New Pathways in Evolution*. Gardner, June 261
Borderline Personality Disorder
Prevalence of cyclothymia in borderline personality disorder. Leavitt, Aug 335–339
Brain Disorders
Bilateral atrophy of the frontal and temporal lobes in schizophrenic patients with Capgras syndrome: a case-control study using computed tomography. Joseph, Aug 322–325
Psychosocial reactions in the spouses of patients suffering polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. Hakola, Jan 21–24
Brain Imaging
Brain-imaging approaches in psychiatry: early developmental considerations. Morihisa, Jan suppl 44–46
Brain imaging as a tool in establishing a theory of brain pathology in obsessive compulsive disorder. Baxter, Feb suppl 22–25, Aug suppl 32–35
Bromocriptine
Psychiatric applications of bromocriptine therapy. Sitland-Marken, Feb 68–82
Bulimia
Hyperamylasemia and binge-purge episodes [letter]. Walsh; Gwirtsman reply, Mar 128–129
Hyperamylasemia in bulimia nervosa. Walsh, Sept 373–377
Bupropion
Bupropion as a promising approach to rapid cycling bipolar II patients. Haykal, Nov 450–455
Bupropion dose, seizures, women, and age [letter]. Goldberg; Davidson reply, Sept 388–389
Bupropion dosing recommendations [letter]. Davidson, Feb 83
Case of bupropion-associated delirium. Dager, July 307–308
Fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. Lineberry, May 194–199
Buspirone
Buspirone in clinical practice. Rickels, Sept suppl 51–54
Buspirone in the management of major depression: a placebo-controlled comparison. Fabre, Sept suppl 55–61
Buspirone therapy for elderly patients with anxiety or depressive neurosis [letter]. Böhm, July 309
Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Udelman, Sept suppl 46–50
Discussant presentation: serotonin partial agonists in the treatment of depression. Dimitriou, Sept suppl 65–66
Double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. Strand, Sept suppl 40–45
Introduction. Serotonin partial agonists in the treatment of anxiety and depression. Dudley Jr, Sept suppl 30
Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. Petracca, Sept suppl 31–39
Cancer
Depression and the cancer patient. Massie, July suppl 12–17
Cannabis
Complex partial seizure symptoms affected by marijuana abuse [letter]. Ellison, Oct 439–440
Capgras Syndrome
Bilateral atrophy of the frontal and temporal lobes in schizophrenic patients with Capgras syndrome: a case-control study using computed tomography. Joseph, Aug 322–325
Edgar Allan Poe's "William Wilson" and Capgras syndrome [letter]. Schneck, Sept 387–388
Carbamazepine
Carbamazepine in behaviorally disturbed primary dementia patients [letter]. Ballinger; Schneider reply, Dec 523–524
Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. Gleason, Mar 115–118

Interaction of fluoxetine with carbamazepine [letter]. Pearson, Mar 126
Non-lithium treatment for bipolar disorder. Post, Aug suppl 9–16
Selective response to carbamazepine in a case of organic mood disorder [letter]. Schneier, Nov 485
Treatment of psychotic symptoms in Alzheimer's patients [letter]. Ankenman; Schneider reply, Oct 437–438
Carbon Dioxide
Effect of long-term imipramine treatment on carbon dioxide-induced anxiety in panic disorder patients. Woods, Dec 505–507
Cardiac Side Effects
Electrocardiogram as a tool for therapeutic monitoring: a critical analysis. Guy, Dec suppl B 37–39
Fluoxetine-induced bradycardia and syncope in two patients. Ellison, Sept 385–386
Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients. Stoudemire, Dec 508–512
Cardiovascular Diseases
Chest pain, cardiac disease, and panic disorder. Katon, May suppl 27–30
ECT in a patient with aortic aneurysm. Devanand, June 255–256
Effect of nortriptyline in elderly patients with cardiac conduction disease. Dietch, Feb 65–67
Perspectives on the relationship between cardiovascular disease and affective disorder. Dalack, July suppl 4–9
Catatonia
Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. Rosebush, Sept 357–362
Problems in diagnosing bipolar disorder in catatonic patients. Fein, May 203–205
Cerebrovascular Disease
Depression and cerebrovascular disease. Robinson, July suppl 26–31
Children
Epidemiologic study of Tourette's syndrome in a single school district. Comings, Nov 463–469
High anxiety in children. Graae, May suppl 18–19
Citalopram
Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. de Montigny, Dec suppl B 4–8
Clomipramine
Bupropion as a promising approach to rapid cycling bipolar II patients. Haykal, Nov 450–455
Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. Greist, July 292–297
Treating the anxiety: therapeutic options in obsessive compulsive disorder. Greist, Nov suppl 29–34
Worldwide use of clomipramine. Trimble, Aug suppl 51–54
Clonazepam
Clonazepam and bipolar affective disorder [letter]. Bansil; Sachs reply, Dec 522–523
Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects. Svebak, May suppl 14–17
Clonazepam for the treatment of social phobia. Reiter, Nov 470–472
Clonazepam in the treatment of social phobia: a pilot study. Munjack, May suppl 35–40
Clonazepam treatment of acute mania in an AIDS patient [letter]. Budman, May 212
Clonazepam treatment of obsessions and compulsions. Hewlett, Apr 158–161
Clonazepam treatment of obsessive compulsive disorder [letter]. Bacher, Apr 168–169
Emerging uses for high-potency benzodiazepines in psychotic disorders. Patterson, May suppl 41–46
High anxiety in children. Graae, May suppl 18–19
Non-lithium treatment for bipolar disorder. Post, Aug suppl 9–16
Use of clonazepam for bipolar affective disorder. Sachs, May suppl 31–34
Withdrawal from alprazolam dependency using clonazepam: clinical observations. Patterson, May suppl 47–49
Clozapine
Avoidance of metoclopramide for the treatment of clozapine-induced nausea [letter]. Jenkins, May 210
Triad of hyperthermia, increased REM sleep, and cataplexy during clozapine treatment [letter]? Blum, June 259–260
Cocaine
Cocaine augments peripheral benzodiazepine binding in humans. Chesley, Oct 404–406
Panic disorder and cocaine abuse in alcoholics [letter]. Yates, Oct 440
Prolonged detection period for cocaine and metabolite [letter]. Weddington, Aug 347
Prolonged presence of metabolite in urine after compulsive cocaine use. Burke, Apr 145–148
Comorbidity
Comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. Clayton, Nov suppl 35–39
Comorbidity of anxiety and depression in generai medical patients: a longitudinal study. Zung, June suppl 77–80
Panic and phobic disorders in patients with obsessive compulsive disorder. Austin, Nov 456–458
Treatment of anxiety disorder in patients with mood disorders. Coplan, Oct suppl 9–13
Understanding and treating depression in anxious patients. Dubovsky, Oct suppl 3–8
Corrections
Diagnosis and treatment of adolescent anxiety disorders. Biederman, May suppl 20–26. Correction, Oct 440
Costs and Cost Analysis
Cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a medicaid population. McCombs, June suppl 60–69
Crohn's Disease
Bipolar disorder and Crohn's disease. Holroyd, Oct 407–409
Cyclothymia
Prevalence of cyclothymia in borderline personality disorder. Leavitt, Aug 335–339
Cyproheptadine
Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. McCormick, Sept 383–384
Dementia see also Alzheimer's Disease
Anticoagulant therapy for dementia [letter]. Walsh, Dec 522
Carbamazepine in behaviorally disturbed primary dementia patients [letter]. Ballinger; Schneider reply, Dec 523–524
Psychosocial reactions in the spouses of patients suffering polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. Hakola, Jan 21–24
Depression see also Bipolar Disorder; Mania; Mood Disorders; Postpartum Depression; Seasonal Affective Disorder
Anxiety disorders during acute bereavement: risk and risk factors. Jacobs, July 269–274
Bereavement and depression. Clayton, July suppl 34–38
Buspirone in the management of major depression: a placebo-controlled comparison. Fabre, Sept suppl 55–61
Buspirone therapy for elderly patients with anxiety or depressive neurosis [letter]. Böhm, July 309
Caffeine-modified electroconvulsive therapy in depressed patients with medical illness. Lurie, Apr 154–157
Comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. Clayton, Nov suppl 35–39
Comorbidity of anxiety and depression in general medical patients: a longitudinal study. Zung, June suppl 77–80
CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. Brown, Apr suppl 31–41
Depression and cerebral stroke. Catapano, Sept suppl 9–12
Depression and cerebrovascular disease. Robinson, July suppl 26–31
Depression and chronic medical illness. Katon, June suppl 3–11
Depression and organic mood disorder [letter]. Clower, Sept 387
Depression and the cancer patient. Massie, July suppl 12–17
Depression and the mediation of chronic pain. Dufton, June 248–250
Depression in the context of human immunodeficiency virus infection: implications for treatment. Hintz, Dec 497–501
Depression in the patient with Parkinson's disease. Mayeux, July suppl 20–23
Double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. March, May 200–202
Efficacy study of single- versus double-seizure induction with ECT in major depression. Roemer, Nov 473–478
Electroconvulsive therapy and major depression in Down's syndrome. Lazarus, Oct 422–425
Electroconvulsive therapy in a patient with severe tic and major depressive episode. Swerdlow, Jan 34–35
Fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. Lineberry, May 194–199
Guidelines for diagnosis and treatment of depression in patients with medical illness. Cameron, July suppl 49–54
Introduction. Diagnosis and treatment of depression in the medical setting. Roose, July suppl 3
Major depression versus organic mood disorder: a questionable distinction. Fogel, Feb 53–56
MAO inhibition and clinical response in depressed patients treated with phenelzine. Bresnahan, Feb 47–50
Personality disorder diagnoses and age in inpatients with major depression. Fogel, June 232–235
PET imaging in obsessive compulsive disorder with and without depression. Baxter, Apr suppl 61–69
Pharmacologic treatment of major depression for elderly patients in residential care settings. Katz, July suppl 41–47
Possible association of Ganser's syndrome and major depression [letter]. Grieger, Oct 437
Practical considerations in the pharmacologic treatment of depression and anxiety in the elderly. Salzman, Jan suppl 40–43
Problems associated with the diagnosis of depression. Rush, June suppl 15–22
Psychopharmacology of depression in neurologic disorders. Silver, Jan suppl 33–39
Psychosocial aspects of depression and the role of psychotherapy. Jarrett, June suppl 26–35
Rapid response of patients simultaneously treated with lithium and nortriptyline. Austin, Mar 124–125
Relapse and recurrence in unipolar major depression: short-term and long-term approaches. Thase, June suppl 51–57
Reverse seasonal affective disorder in major depressive disorder [letter]. Milstein, Apr 167–168
Role of rating scales in the identification and management of the depressed patient in the primary care setting. Zung, June suppl 72–76
Targeting treatment in patients with mixed symptoms of anxiety and depression. Fawcett, Nov suppl 40–43
Treatment-resistant depression: definition and treatment approaches. Nierenberg AA, June suppl 39–47
Understanding and treating depression in anxious patients. Dubovsky, Oct suppl 3–8
Unusual lymphocyte subset distribution in some depressed patients. Wilson, Feb 51–52
What constitutes an adequate antidepressant trial for fluoxetine? Schweizer, Jan 8–11
Winter depression responds to an open trial of tranylcypromine. Dilsaver, Aug 326–329
Desipramine
Role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. Nathan, Sept 367–372
Diagnosis/Classification
DSM-III-R classification of murderous youth: help or hindrance? Myers, June 239–242
Major depression versus organic mood disorder: a questionable distinction. Fogel, Feb 53–56
Psychiatric diagnoses and chronic fatigue syndrome [letter]. Bradley; Kruesi reply, Feb 86
Retrospective assessment of DSM-III attention deficit disorder in nonreferred individuals. Biederman, Mar 102–106
Schizophrenic individuals with bipolar first-degree relatives [letter]. Menuck, Sept 389
Diagnosis, Differential
Anxiety and mood disorders in medically ill patients. Wise, Jan suppl 27–32
Case of autoimmune thyroiditis presenting as menstrual related mood disorder. Schmidt, Oct 434–436
Comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. Clayton, Nov suppl 35–39
Depression and organic mood disorder [letter]. Clower, Sept 387
Diagnosis and treatment of adolescent anxiety disorders. Biederman, May suppl 20–26. Correction, Oct 440
Koro or hysteria [letter]? Sheeley; Westermeyer reply, Jan 39

Problems associated with the diagnosis of depression. Rush, June suppl 15–22
Problems in diagnosing bipolar disorder in catatonic patients. Fein, May 203–205
Review of clinical approaches to gender dysphoria. Brown, Feb 57–64
Shared features of neuroleptic malignant syndrome and alcohol abuse complications [letter]. Krystal, Dec 523
Usefulness of screening EEGs in a psychiatric inpatient population. Warner, Sept 363–364
Diazepam
Subjective feelings of anxiety in young men after ethanol and diazepam infusions. Monteiro, Jan 12–16
Disulfiram
Disulfiram-induced fulminating hepatitis and monitoring guidelines [letter]. Phillips, Apr 168
Dopamine
Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? Goodman, Aug suppl 36–43
Postpartum psychosis with abnormal movements: dopamine supersensitivity unmasked by withdrawal of endogenous estrogens? Vinogradov, Sept 365–366
Treatment of tardive dystonia [letter]. Friedman, Aug 348
Dosage
Bupropion dose, seizures, women, and age [letter]. Goldberg; Davidson reply, Sept 388–389
Bupropion dosing recommendations [letter]. Davidson, Feb 83
Fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. Lineberry, May 194–199
Is relapse a justification for the use of high-dose antipsychotics [letter]? Cohen; McCormick reply, Nov 486–487
Neuroleptic dosage regimens in psychotic inpatients: a retrospective comparison. Vuckovic, Mar 107–109
Role for high-dose antipsychotics. Brotman, Apr 164–166
Trazodone dosing regimen: experience with single daily administration. Fabre, Sept suppl 23–26
What constitutes an adequate antidepressant trial for fluoxetine? Schweizer, Jan 8–11
Dose-Response Relationship
Imipramine equivalents [letter]. Kantor; Weilburg reply, June 257
Down's Syndrome
Electroconvulsive therapy and major depression in Down's syndrome. Lazarus, Oct 422–425
Drug Addiction
Tranylcypromine addiction: a case report and review. Briggs, Oct 426–429
Drug Interactions
Adverse consequences of fluoxetine-MAOI combination therapy. Feighner, June 222–225
Case of delirium secondary to phenelzine/L-tryptophan combination [letter]. Alvine, July 311
Increased plasma nortriptyline concentration in a patient cotreated with fluoxetine [letter]. Kahn, Jan 36
Interaction of fluoxetine with carbamazepine [letter]. Pearson, Mar 126
MAOIs, OTC drugs, and hypertensive crisis [letters]. Golwyn; Magurno; Harrison reply, May 212–213
Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. Austin, Aug 344–345
Drug Side Effects see also specific effect
Antidepressant drug side effects. Cole, Jan suppl 21–26
Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. Hamann, Dec 502–504
Drug Therapy, Combination
Adverse consequences of fluoxetine-MAOI combination therapy. Feighner, June 222–225
Bupropion as a promising approach to rapid cycling bipolar II patients. Haykal, Nov 450–455
Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Hollander, Mar 119–123
Rapid response of patients simultaneously treated with lithium and nortriptyline. Austin, Mar 124–125
Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. Austin, Aug 344–345
Valproate use in the older manic patient. McFarland, Nov 479–481
DSM-III-R see Diagnosis/Classification
Dyskinesia, Drug-Induced
Acute dystonia and fluoxetine [letter]. Reccoppa, Nov 487
Crossover study of lecithin treatment of tardive dyskinesia. Gelenberg, Apr 149–153
Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Singh, Aug 319–321
Tardive dyskinesia presenting as gastrointestinal disorder. Goldberg, June 253–254
Dystonia
Acute dystonia and fluoxetine [letter]. Reccoppa, Nov 487
Tardive dystonia: four case histories. Yadalam, Jan 17–20
Treatment of tardive dystonia [letter]. Friedman, Aug 348
Eating Disorders
Hyperamylasemia and binge-purge episodes [letters]. Blinder; Larocca;Walsh; Gwirtsman reply, Mar 128–129
ECT see Electroconvulsive Therapy
Edema
Methadone and edema [letter]. Macfadden, Jan 36–37
Editorials
The *Journal* in focus [editorial]. Gelenberg, Mar 94
Professionalism: sane and insane [editorial]. Racy, Apr 138–140
EEG see Electroencephalography
Elderly Patients see Geriatric Psychiatry
Electrocardiogram
Electrocardiogram as a tool for therapeutic monitoring: a critical analysis. Guy, Dec suppl B 37–39
Electroconvulsive Therapy
Blood pressure reduction with ECT response. Swartz, Oct 414–416
Caffeine-modified electroconvulsive therapy in depressed patients with medical illness. Lurie, Apr 154–157
ECT in a patient with aortic aneurysm. Devanand, June 255–256
Efficacy study of single- versus double-seizure induction with ECT in major depression. Roemer, Nov 473–478
Electroconvulsive therapy and major depression in Down's syndrome. Lazarus, Oct 422–425
Electroconvulsive therapy in a patient with severe tic and major depressive episode. Swerdlow, Jan 34–35
Is maintenance ECT effective [letter]? Andrade; Thienhaus reply, Nov 485–486
Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients. Stoudemire, Dec 508–512
Monitoring seizure duration during ECT [letter]. Kramer; Guze reply, Jan 38–39
Study of the clinical efficacy of maintenance ECT. Thienhaus, Apr 141–144
Electroencephalography
Monitoring seizure duration during ECT [letter]. Kramer; Guze reply, Jan 38–39
Usefulness of screening EEGs in a psychiatric inpatient population. Warner, Sept 363–364
Estrogen
Postpartum psychosis with abnormal movements: dopamine supersensitivity unmasked by withdrawal of endogenous estrogens? Vinogradov, Sept 365–366
Fatigue
Afternoon fatigue and somnolence associated with tranylcypromine treatment. Joffe, May 192–193
Chronic fatigue syndrome [letter]. Reiss, Apr 169
Psychiatric diagnoses and chronic fatigue syndrome [letter]. Bradley; Kruesi reply, Feb 86
Fenfluramine
Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Hollander, Mar 119–123
Flerlage, Stuart Q: Tribute
Sculptor of damaged souls [letter]. Beauchamp, June 257–258
Fluoxetine
Acute dystonia and fluoxetine [letter]. Reccoppa, Nov 487
Adverse consequences of fluoxetine-MAOI combination therapy. Feighner, June 222–225
Akathisia and fluoxetine [letter]. Maany; Lipinski reply, May 210–212
Clinical overview of serotonin reuptake inhibitors. Rickels, Dec suppl B 9–12
Excretion of fluoxetine in human breast milk [letter]. Isenberg, Apr 169
Fluoxetine and stuttering [letter]. Friedman; Guthrie reply, July 310–311
Fluoxetine-induced akathisia in male OCD patients [letter]. Friedman, May 212
Fluoxetine-induced bradycardia and syncope in two patients. Ellison, Sept 385–386
Fluoxetine-induced mania [letter]. Feder, Dec 524–525
Fluoxetine-induced sexual dysfunction. Herman, Jan 25–27
Fluoxetine-induced stuttering (letter). Guthrie, Feb 85
Fluoxetine treatment of anorexia nervosa: an open clinical trial. Gwirtsman, Sept 378–382
Fluoxetine treatment of premenstrual syndrome [letter]. Metz, June 260
Fluoxetine treatment of premenstrual syndrome [letter]. Pies, Aug 348
Increased plasma nortriptyline concentration in a patient cotreated with fluoxetine [letter]. Kahn, Jan 36
Interaction of fluoxetine with carbamazepine [letter]. Pearson, Mar 126
Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. McCormick, Sept 383–384
Serotonergic activity and hostility [letter]. Everett; Sabelli reply, Oct 438–439
Successful fluoxetine treatment of pathologic jealousy. Lane, Aug 345–346
What constitutes an adequate antidepressant trial for fluoxetine? Schweizer, Jan 8–11
Fluvoxamine
Clinical overview of serotonin reuptake inhibitors. Rickels, Dec suppl B 9–12
Double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. March, May 200–202
Role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. Nathan, Sept 367–372
Ganser Syndrome
Ganser syndrome: a case report [letter]. Mahadevappa, Apr 167
Possible association of Ganser's syndrome and major depression [letter]. Grieger, Oct 437
Gastrointestinal System
Tardive dyskinesia presenting as gastrointestinal disorder. Goldberg, June 253–254
Gender see Sex Differences
Gender Identity Disorders
Review of clinical approaches to gender dysphoria. Brown, Feb 57–64
Genetics
Controlled family history study of Tourette's syndrome, I: attention-deficit hyperactivity disorder and learning disorders. Comings, July 275–280
Controlled family history study of Tourette's syndrome, II: alcoholism, drug abuse, and obesity. Comings, July 281–287
Controlled family history study of Tourette's syndrome, III: affective and other disorders. Comings, July 288–291
Schizophrenic individuals with bipolar first-degree relatives: analysis of two pedigrees. Pope Jr, Mar 97–101
Geriatric Psychiatry
Anxiety in the elderly: treatment strategies. Salzman, Oct suppl 18–21
Buspirone therapy for elderly patients with anxiety or depressive neurosis [letter]. Böhm, July 309
Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. Cohn, Dec suppl B 28–33
Effect of nortriptyline in elderly patients with cardiac conduction disease. Dietch, Feb 65–67
Effects of sertraline on psychomotor performance in elderly volunteers. Hindmarch, Dec suppl B 34–36
Geriatric psychiatry: an update. Kalayam, May 177–183
Personality disorder diagnoses and age in inpatients with major depression. Fogel, June 232–235
Pharmacologic management of aggression in the elderly. Yudofsky, Oct suppl 22–28
Pharmacologic treatment of major depression for elderly patients in residential care settings. Katz, July suppl 41–47
Practical considerations in the pharmacologic treatment of depression and anxiety in the elderly. Salzman, Jan suppl 40–43
Study of the clinical efficacy of maintenance ECT. Thienhaus, Apr 141–144
Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. Austin, Aug 344–345
Valproate use in the older manic patient. McFarland, Nov 479–481
Violence by geriatric patients who need psychiatric

hospitalization. Kalunian, Aug 340–343
Gilles de la Tourette's Disease
Controlled family history study of Tourette's syndrome, I: attention-deficit hyperactivity disorder and learning disorders. Comings, July 275–280
Controlled family history study of Tourette's syndrome, II: alcoholism, drug abuse, and obesity. Comings, July 281–287
Controlled family history study of Tourette's syndrome, III: affective and other disorders. Comings, July 288–291
Epidemiologic study of Tourette's syndrome in a single school district. Comings, Nov 463–469
Grief
Anxiety disorders during acute bereavement: risk and risk factors. Jacobs, July 269–274
Bereavement and depression. Clayton, July suppl 34–38
Haloperidol
Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. Hamann, Dec 502–504
Hepatitis
Disulfiram-induced fulminating hepatitis and monitoring guidelines [letter]. Phillips, Apr 168
5-HIAA see 5-Hydroxyindoleacetic Acid
Hoarding
Hoarding as a psychiatric symptom. Greenberg, Oct 417–421
Homicide
DSM-III-R classification of murderous youth: help or hindrance? Myers, June 239–242
Homicide and near-homicide by anabolic steroid users. Pope Jr, Jan 28–31
Human Immunodeficiency Virus
Depression in the context of human immunodeficiency virus infection: implications for treatment. Hintz, Dec 497–501
5-Hydroxyindoleacetic Acid
CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. Brown, Apr suppl 31–41
Postmortem evidence for serotonin's role in suicide. Stanley, Apr suppl 22–28
Hyperamylasemia
Hyperamylasemia and binge-purge episodes [letters]. Blinder; Larocca; Walsh; Gwirtsman reply, Mar 128–129
Hyperamylasemia in bulimia nervosa. Walsh, Sept 373–377
Hypertension
Blood pressure reduction with ECT response. Swartz, Oct 414–416
MAOIs, OTC drugs, and hypertensive crisis [letters]. Golwyn; Magurno; Harrison reply, May 212–213
Hyperthermia
Treatment of rehospitalized NMS patients [letter]. Lazarus, Feb 84
Triad of hyperthermia, increased REM sleep, and cataplexy during clozapine treatment [letter]? Blum, June 259–260
Hypnosis
New uses of hypnosis in the treatment of posttraumatic stress disorder. Spiegel, Oct suppl 39–43
Hypotension
Postural hypotension in chronically medicated schizophrenics. Silver, Nov 459–462
Imipramine
Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects. Svebak, May suppl 14–17
Double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. March, May 200–202
Effect of long-term imipramine treatment on carbon dioxide-induced anxiety in panic disorder patients. Woods, Dec 505–507
Imipramine equivalents [letter]. Kantor; Weilburg reply, June 257
Imipramine treatment of panic disorder during pregnancy. Ware, Nov 482–484
Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia. Mavissakalian, May 184–188
Immune System
Unusual lymphocyte subset distribution in some depressed patients. Wilson, Feb 51–52
Impulsive Behavior
CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. Brown, Apr suppl 31–41
Insomnia
Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. Jacobsen, July 298–302
Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. Scharf, Sept suppl 13–17
Isoniazid
Isoniazid-induced obsessive compulsive neurosis [letter]. Bhatia, Sept 387
Jealousy
Successful fluoxetine treatment of pathologic jealousy. Lane, Aug 345–346
Journal of Clinical Psychiatry
Editorial: *Journal* in focus [editorial]. Gelenberg, Mar 94
Koro
Koro or hysteria (letter)? Sheeley; Westermeyer reply, Jan 39
Labetalol
Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients. Stoudemire, Dec 508–512
Learning Disorder
Controlled famiiy history study of Tourette's syndrome, I: attention-deficit hyperactivity disorder and learning disorders. Comings, July 275–280
Lecithin
Crossover study of lecithin treatment of tardive dyskinesia. Gelenberg, Apr 149–153
Lithium see also ACADEMIC HIGHLIGHTS
Compliance, the LAQ, and a new laboratory method of measuring RBC lithium [letter]. Harvey, Mar 126–127
Lithium-induced worsening of wintertime depression in a bipolar patient [letter]. Dilsaver, Aug 347–348
Lithium: the present and the future. Jefferson, Aug suppl 4–8
Lithium therapy and prophylaxis [letter]. Andrade; Jefferson reply, Jan 37–38
Lithium treatment during pregnancy, delivery, and lactation: an update. Schou, Oct 410–413
Pseudotumor cerebri associated with lithium therapy in two patients. Levine, June 251–253
Rapid response of patients simultaneously treated with lithium and nortriptyline. Austin, Mar 124–125
Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. Austin, Aug 344–345
Lorazepam
Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. Rosebush, Sept 357–362
Maintenance Treatment
Is maintenance ECT effective [letter]? Andrade; Thienhaus reply, Nov 485–486
Maintenance treatment with antidepressants in panic disorder. Noyes Jr, Dec suppl A 24–30
Study of the clinical efficacy of maintenance ECT. Thienhaus, Apr 141–144
Mania
Clonazepam treatment of acute mania in an AIDS patient [letter]. Budman, May 212
Fluoxetine-induced mania [letter]. Feder, Dec 524–525
Medical Illness
Anxiety and mood disorders in medically ill patients. Wise, Jan suppl 27–32
Caffeine-modified electroconvulsive therapy in depressed patients with medical illness. Lurie, Apr 154–157
Depression and chronic medical illness. Katon, June suppl 3–11
Depression in sleep apnea: a different view [letter]. Lee, July 309–310
Guidelines for diagnosis and treatment of depression in patients with medical illness. Cameron, July suppl 49–54
Psychiatric diagnoses and chronic fatigue syndrome [letter]. Bradley; Kruesi reply, Feb 86
Menstrual Cycle
Case of autoimmune thyroiditis presenting as menstrual related mood disorder. Schmidt, Oct 434–436
Mental Retardation
Electroconvulsive therapy and major depression in Down's syndrome. Lazarus, Oct 422–425
Methadone
Methadone and edema [letter]. Macfadden, Jan 36–37
Metoclopramide
Avoidance of metoclopramide for the treatment of clozapine-induced nausea [letter]. Jenkins, May 210
Milk, Human
Excretion of fluoxetine in human breast milk [letter]. Isenberg, Apr 169
Monoamine Oxidase Inhibitors
Adverse consequences of fluoxetine-MAOI combination therapy. Feighner, June 222–225
Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. Jacobsen, July 298–302
MAO inhibition and clinical response in depressed patients treated with phenelzine. Bresnahan, Feb 47–50
MAOIs, OTC drugs, and hypertensive crisis [letters]. Golwyn; Magurno; Harrison reply, May 212–213
Monosodium glutamate and tranylcypromine administration in healthy subjects. Balon, July 303–306
Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants. Clary, June 226–231
Monosodium Glutamate
Monosodium glutamate and tranylcypromine administration in healthy subjects. Balon, July 303–306
Mood Disorders
Anxiety and mood disorders in medically ill patients. Wise, Jan suppl 27–32
Major depression versus organic mood disorder: a questionable distinction. Fogel, Feb 53–56
Perspectives on the relationship between cardiovascular disease and affective disorder. Dalack, July suppl 4–9
Spectrum of mood disorders. Lopez-Ibor Jr, Sept suppl 62–64
Study of the clinical efficacy of maintenance ECT. Thienhaus, Apr 141–144
Treatment of anxiety disorder in patients with mood disorders. Coplan, Oct suppl 9–13
Mutism
Phenelzine treatment of elective mutism: a case report. Golwyn, Sept 384–385
Nausea
Avoidance of metoclopramide for the treatment of clozapine-induced nausea [letter]. Jenkins, May 210
Neuroleptic Malignant Syndrome
Shared features of neuroleptic malignant syndrome and alcohol abuse complications [letter]. Krystal, Dec 523
Treatment of rehospitalized NMS patients [letter]. Lazarus, Feb 84
Neuroleptics see Tranquilizing Agents, Major
Neurologic Disorders
Psychopharmacology of depression in neurologic disorders. Silver, Jan suppl 33–39
Neurotransmitters
Role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. Blier, Apr suppl 14–20
Serotonin receptor and reuptake sites: pharmacologic significance. Gonzalez-Heydrich, Apr suppl 5–12
Nifedipine
MAOIs, OTC drugs, and hypertensive crisis [letters]. Golwyn; Magurno; Harrison reply, May 212–213
Nortriptyline
Effect of nortriptyline in elderly patients with cardiac conduction disease. Dietch, Feb 65–67
Increased plasma nortriptyline concentration in a patient cotreated with fluoxetine [letter]. Kahn, Jan 36
Rapid response of patients simultaneously treated with lithium and nortriptyline. Austin, Mar 124–125
Obsessive Compulsive Disorder
Approaches to the patient with treatment-refractory obsessive compulsive disorder. Jenike, Feb suppl 15–21
Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? Goodman, Aug suppl 36–43
Brain imaging as a tool in establishing a theory of brain pathology in obsessive compulsive disorder. Baxter, Feb suppl 22–25, Aug suppl 32–35
Chronic anxiety. deciding the length of treatment. Gorman, Jan suppl 11–15
Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. Greist, July 292–297
Clonazepam treatment of obsessions and compulsions. Hewlett, Apr 158–161
Clonazepam treatment of obsessive compulsive dis-

order [letter]. Bacher, Apr 168–169
Comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. Murphy, Apr suppl 53–58
Epidemiology of obsessive compulsive disorder. Rasmussen, Feb suppl 10–13, Aug suppl 20–23
Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Hollander, Mar 119–123
Fluoxetine-induced akathisia in male OCD patients [letter]. Friedman, May 212
Introduction. Recent advances in bipolar and obsessive compulsive disorders: nature and treatment. Greist, Aug suppl 3
Isoniazid-induced obsessive compulsive neurosis [letter]. Bhatia, Sept 387
Lack of a compulsivity continuum disputed [letter]. Frattaroli; Pitman reply, Jenike reply, Aug 349–350
Neurobiology of obsessive compulsive disorder: a possible role for serotonin. Winslow, Aug suppl 27–31
New pharmacologic approaches to obsessive compulsive disorder. Insel, Oct suppl 47–51
Panic and phobic disorders in patients with obsessive compulsive disorder. Austin, Nov 456–458
PET imaging in obsessive compulsive disorder with and without depression. Baxter, Apr suppl 61–69
Pharmacotherapy of moral or religious scrupulosity. Fallon, Dec 517–521
Phenomenology of obsessive compulsive disorder. Insel, Feb suppl 4–8
Preface. Obsessive compulsive disorder: new perspectives. Insel, Feb suppl 3
Treating the anxiety: therapeutic options in obsessive compulsive disorder. Greist, Nov suppl 29–34
Treatment of obsessive compulsive disorder: psychotherapies, drugs, and other somatic treatment. Greist, Aug suppl 44–50
Treatment of psychotic symptoms in OCD patients [letter]. Deckert, June 259
Waking nightmare: an overview of obsessive compulsive disorder. Rapoport, Nov suppl 25–28
Worldwide use of clomipramine. Trimble, Aug suppl 51–54

Organic Mental Disorders
Depression and organic mood disorder [letter]. Clower, Sept 387
Selective response to carbamazepine in a case of organic mood disorder [letter]. Schneier, Nov 485
Violence by geriatric patients who need psychiatric hospitalization. Kalunian, Aug 340–343

Oxazepam
Double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. Strand, Sept suppl 40–45

Pain
Depression and the mediation of chronic pain. Dufton, June 248–250

Panic
Chest pain, cardiac disease, and panic disorder. Katon, May suppl 27–30
Chronic anxiety: deciding the length of treatment. Gorman, Jan suppl 11–15
Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects. Svebak, May suppl 14–17
Comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. Murphy, Apr suppl 53–58
Continuation treatment of panic disorder with high-potency benzodiazepines. Davidson, Dec suppl A 31–37
Drug preferences of alcoholic polydrug abusers with and without panic. Jensen, May 189–191
Effect of long-term imipramine treatment on carbon dioxide-induced anxiety in panic disorder patients. Woods, Dec 505–507
Hidden patient: unrecognized panic disorder. Weissman, Nov suppl 5–8
High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience. Tesar, May suppl 4–10
Imipramine treatment of panic disorder during pregnancy. Ware, Nov 482–484
Introduction. Panic disorder: diathesis and treatment issues. Rosenbaum, Dec suppl A 3–4
Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic study. Pollack, Dec suppl A 12–16
Long-term management of panic disorder. Pollack, May suppl 11–13
Long-term outcome for patients with panic disorder treated with cognitive-behavioral therapy. Barlow, Dec suppl A 17–23
Maintenance treatment with antidepressants in panic disorder. Noyes Jr, Dec suppl A 24–30
Managing long-term therapy for panic disorder. Burrows, Nov suppl 9–12
Noradrenergic function in panic disorder. Charney, Dec suppl A 5–11
Panic and phobic disorders in patients with obsessive compulsive disorder. Austin, Nov 456–458
Panic disorder and cocaine abuse in alcoholics [letter]. Yates, Oct 440
Patients with frequent sleep panic: clinical findings and response to medication treatment. Mellman, Dec 513–516
Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia. Mavissakalian, May 184–188
Summary. Rosenbaum, Dec suppl A 46
Thinking about stopping treatment for panic disorder. DuPont, Dec suppl A 38–45

Parkinson's Disease
Depression in the patient with Parkinson's disease. Mayeux, July suppl 20–23

Perphenazine
Relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. Mazure, Aug 330–334

Personality Disorders
Personality disorder diagnoses and age in inpatients with major depression. Fogel, June 232–235

PET see Positron Emission Tomography

Phenelzine
Case of delirium secondary to phenelzine/L-tryptophan combination [letter]. Alvine, July 311
MAO inhibition and clinical response in depressed patients treated with phenelzine. Bresnahan, Feb 47–50
Phenelzine treatment of elective mutism: a case report. Golwyn, Sept 384–385

Phobias
Chronic anxiety: deciding the length of treatment. Gorman, Jan suppl 11–15
Clonazepam for the treatment of social phobia. Reiter, Nov 470–472
Clonazepam in the treatment of social phobia: a pilot study. Munjack, May suppl 35–40
Panic and phobic disorders in patients with obsessive compulsive disorder. Austin, Nov 456–458
Treatment of social phobias. Agras, Oct suppl 52–55

Physostigmine
Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type. Jenike, Jan 3–7

Polycystic Lipomembranous Osteodysplasia
Psychosocial reactions in the spouses of patients suffering polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. Hakola, Jan 21–24

Positron Emission Tomography
Brain imaging as a tool in establishing a theory of brain pathology in obsessive compulsive disorder. Baxter, Feb suppl 22–25, Aug suppl 32–35
PET imaging in obsessive compulsive disorder with and without depression. Baxter, Apr suppl 61–69

Postpartum Depression
Excretion of fluoxetine in human breast milk [letter]. Isenberg, Apr 169

Postpartum Psychosis
Postpartum psychosis with abnormal movements: dopamine supersensitivity unmasked by withdrawal of endogenous estrogens? Vinogradov, Sept 365–366

Posttraumatic Stress Disorder
Alexithymia among Vietnam veterans with posttraumatic stress disorder. Hyer, June 243–247
Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Braun, June 236–238
New approaches in the pharmacotherapy of posttraumatic stress disorder. Silver, Oct suppl 33–38
New uses of hypnosis in the treatment of posttraumatic stress disorder. Spiegel, Oct suppl 39–43
Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. Risse, May 206–209

Pregnancy
Imipramine treatment of panic disorder during pregnancy. Ware, Nov 482–484
Lithium treatment during pregnancy, delivery, and lactation: an update. Schou, Oct 410–413

Premenstrual Syndrome
Fluoxetine treatment of premenstrual syndrome [letter]. Metz, June 260
Fluoxetine treatment of premenstrual syndrome [letter]. Pies, Aug 348

Pseudotumor Cerebri
Pseudotumor cerebri associated with lithium therapy in two patients. Levine, June 251–253

Psychiatrists
Professionalism: sane and insane [editorial]. Racy, Apr 138–140

Psychomotor Performance
Effects of sertraline on psychomotor performance in elderly volunteers. Hindmarch, Dec suppl B 34–36

Psychopharmacology
Generalized anxiety disorder: new concepts and psychopharmacologic therapies. Dubovsky, Jan suppl 3–10
Psychopharmacology of depression in neurologic disorders. Silver, Jan suppl 33–39

Psychosis
Haircutting and psychosis revisited [letter]. Ryken, Feb 83
Neuroleptic dosage regimens in psychotic inpatients: a retrospective comparison. Vuckovic, Mar 107–109
Relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. Mazure, Aug 330–334

Psychosocial Support
Psychosocial reactions in the spouses of patients suffering polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. Hakola, Jan 21–24

Psychotherapy
Combining antidepressants and psychotherapy: rationale and strategies. Perry, Jan suppl 16–20
Psychosocial aspects of depression and the role of psychotherapy. Jarrett, June suppl 26–35

Relapse
Antidepressant tachyphylaxis [letter]. Lieb, Jan 36
Relapse and recurrence in unipolar major depression: short-term and long-term approaches. Thase, June suppl 51–57

Schizophrenia
Bilateral atrophy of the frontal and temporal lobes in schizophrenic patients with Capgras syndrome: a case-control study using computed tomography. Joseph, Aug 322–325
Brain-imaging approaches in psychiatry: early developmental considerations. Morihisa, Jan suppl 44–46
Haircutting and psychosis revisited [letter]. Ryken, Feb 83
Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Singh, Aug 319–321
Postural hypotension in chronically medicated schizophrenics. Silver, Nov 459–462
Schizophrenic individuals with bipolar first-degree relatives: analysis of two pedigrees. Pope Jr, Mar 97–101
Schizophrenic individuals with bipolar first-degree relatives [letter]. Menuck, Sept 389

Sclerosing Leukoencephalopathy
Psychosocial reactions in the spouses of patients suffering polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. Hakola, Jan 21–24

Scrupulosity
Pharmacotherapy of moral or religious scrupulosity. Fallon, Dec 517–521

Seasonal Affective Disorder
Effect of L-tryptophan on seasonal affective disorder. McGrath, Apr 162–163
Lithium-induced worsening of wintertime depression in a bipolar patient [letter]. Dilsaver, Aug 347–348
Onset of winter depression earlier than generally thought [letter]? Dilsaver, June 258
Reverse seasonal affective disorder in major depressive disorder [letter]. Milstein, Apr 167–168
Winter depression responds to an open trial of tranylcypromine. Dilsaver, Aug 326–329

Seizures
Bupropion dose, seizures, women, and age [letter]. Goldberg; Davidson reply, Sept 388–389
Complex partial seizure symptoms affected by marijuana abuse [letter]. Ellison, Oct 439–440
Monitoring seizure duration during ECT [letter]. Kramer; Guze reply, Jan 38–39

Serotonin
Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. Price, Apr suppl 44–50
Clinical overview of serotonin reuptake inhibitors. Rickels, Dec suppl B 9–12
Comparative examination of a role for serotonin in

obsessive compulsive disorder, panic disorder, and anxiety. Murphy, Apr suppl 53–58
CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. Brown, Apr suppl 31–41
Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Hollander, Mar 119–123
Introduction. Coppen, Dec suppl B 3
Introduction. Serotonin and its effects on human behavior. Paul, Apr suppl 3–4
Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. de Montigny, Dec suppl B 4–8
Neurobiology of obsessive compulsive disorder: a possible role for serotonin. Winslow, Aug suppl 27–31
Postmortem evidence for serotonin's role in suicide. Stanley, Apr suppl 22–28
Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. Koe, Dec suppl B 13–17
Role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. Blier, Apr suppl 14–20
Serotonergic activity and hostility [letter]. Everett; Sabelli reply, Oct 438–439
Serotonin receptor and reuptake sites: pharmacologic significance. Gonzalez-Heydrich, Apr suppl 5–12
Waking nightmare: an overview of obsessive compulsive disorder. Rapoport, Nov suppl 25–28

Sertraline
Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled multicenter comparison study in outpatients with major depression. Reimherr, Dec suppl B 18–27
Clinical overview of serotonin reuptake inhibitors. Rickels, Dec suppl B 9–12
Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. Cohn, Dec suppl B 28–33
Effects of sertraline on psychomotor performance in elderly volunteers. Hindmarch, Dec suppl B 34–36
Electrocardiogram as a tool for therapeutic monitoring: a critical analysis. Guy, Dec suppl B 37–39
Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. Koe, Dec suppl B 13–17

Sex Differences
Relationship of gender to violent behavior in acutely disturbed psychiatric patients. Binder, Mar 110–114

Sexual Disorders
Fluoxetine-induced sexual dysfunction. Herman, Jan 25–27
Psychotropic medication and priapism: a comprehensive review. Thompson Jr, Oct 430–433
Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. McCormick, Sept 383–384
Treatment of clomipramine-induced anorgasmia with yohimbine: a case report. Price, Jan 32–33

Sleep
Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. Ware, Sept suppl 18–22
Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. Scharf, Sept suppl 13–17

Sleep Apnea
Depression in sleep apnea: a different view [letter]. Lee, July 309–310

Steroids
Homicide and near-homicide by anabolic steroid users. Pope Jr, Jan 28–31
Implied power of the ministry [letter]? Schmitz, Oct 438
Psychology of anabolic steroid use [letter]. McGraw, June 260

Stress
Anxiety and adjustment disorder: a treatment approach. Schatzberg, Nov suppl 20–24
Paradoxical stress response: a possible common basis for depression and other conditions. Silvestrini, Sept suppl 6–8
Psychosocial stressors and adjustment disorder: Van Gogh's life chart illustrates stress and disease. Rahe, Nov suppl 13–19

Stroke
Depression and cerebral stroke. Catapano, Sept suppl 9–12

Stuttering
Fluoxetine and stuttering [letter]. Friedman; Guthrie reply, July 310–311
Fluoxetine-induced stuttering [letter]. Guthrie, Feb 85

Substance Abuse
Drug preferences of alcoholic polydrug abusers with and without panic. Jensen, May 189–191
Panic disorder and cocaine abuse in alcoholics [letter]. Yates, Oct 440

Substance Withdrawal Syndrome
Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Udelman, Sept suppl 46–50
Emerging uses for high-potency benzodiazepines in psychotic disorders. Patterson, May suppl 41–46
Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. Risse, May 206–209
Withdrawal from alprazolam dependency using clonazepam. Patterson, May suppl 47–49

Suicide
Postmortem evidence for serotonin's role in suicide. Stanley, Apr suppl 22–28

Supersensitivity Psychosis
Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Singh, Aug 319–321

Sweating
Pathophysiology of tricyclic-induced sweating [letter]. Leeman, June 258–259

Tardive Dyskinesia see Dyskinesia, Drug-Induced

Tardive Dystonia see Dystonia

Tests, Psychologic
Depression and the mediation of chronic pain. Dufton, June 248–250
Role of rating scales in the identification and management of the depressed patient in the primary care setting. Zung, June suppl 72–76

Thyroid Disorders
Case of autoimmune thyroiditis presenting as menstrual related mood disorder. Schmidt, Oct 434–436

Tics
Electroconvulsive therapy in a patient with severe tic and major depressive episode. Swerdlow, Jan 34–35

Tinnitus
Tinnitus associated with amitriptyline [letter]. Feder, Feb 85–86

Tolerance
Antidepressant tachyphylaxis [letter]. Lieb, Jan 36

Tranquilizing Agents, Major
Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. Gleason, Mar 115–118
Is relapse a justification for the use of high-dose antipsychotics [letter]? Cohen; McCormick reply, Nov 486
Neuroleptic dosage regimens in psychotic inpatients: a retrospective comparison. Vuckovic, Mar 107–109
Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Singh, Aug 319–321
Postural hypotension in chronically medicated schizophrenics. Silver, Nov 459–462
Role for high-dose antipsychotics. Brotman, Apr 164–166
Treatment of psychotic symptoms in OCD patients [letter]. Deckert, June 259
Treatment of rehospitalized NMS patients [letter]. Lazarus, Feb 84

Transsexualism
Review of clinical approaches to gender dysphoria. Brown, Feb 57–64

Tranylcypromine
Afternoon fatigue and somnolence associated with tranylcypromine treatment. Joffe, May 192–193
Monosodium glutamate and tranylcypromine administration in healthy subjects. Balon, July 303–306
Onset of winter depression earlier than generally thought [letter]? Dilsaver, June 258
Tranylcypromine addiction: a case report and review. Briggs, Oct 426–429
Winter depression responds to an open trial of tranylcypromine. Dilsaver, Aug 326–329

Trazodone
Depression and cerebral stroke. Catapano, Sept suppl 9–12
Drug utilization review of prescribing patterns for trazodone versus amitriptyline. Bryant, Sept suppl 27–29
Guest editor's comments. Scharf, Sept suppl 3
Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. Ware, Sept suppl 18–22
Introduction. Insights in the use of trazodone in depressed patients. Gershon, Sept suppl 4–5
Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. Jacobsen, July 298–302
Paradoxical stress response: a possible common basis for depression and other conditions. Silvestrini, Sept suppl 6–8
Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. Scharf, Sept suppl 13–17
Trazodone dosing regimen: experience with single daily administration. Fabre, Sept suppl 23–26

Tryptophan
Case of delirium secondary to phenelzine/L-tryptophan combination [letter]. Alvine, July 311
Effect of L-tryptophan on seasonal affective disorder. McGrath, Apr 162–163

Tuberculosis
Isoniazid-induced obsessive compulsive neurosis [letter]. Bhatia, Sept 387

Valproate
Non-lithium treatment for bipolar disorder. Post, Aug suppl 9–16
Selective response to carbamazepine in a case of organic mood disorder [letter]. Schneier, Nov 485
Valproate in the treatment of temper outbursts [letter]. Giakas, Dec 525
Valproate use in the older manic patient. McFarland, Nov 479–481

Verapamil
Non-lithium treatment for bipolar disorder. Post, Aug suppl 9–16
Verapamil for violent patients [letter]. Greendyke, Feb 83–84

Violence
Carbamazepine in behaviorally disturbed primary dementia patients [letter]. Ballinger; Schneider reply, Dec 523–524
CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. Brown, Apr suppl 31–41
Pharmacologic management of aggression in the elderly. Yudofsky, Oct suppl 22–28
Relationship of gender to violent behavior in acutely disturbed psychiatric patients. Binder, Mar 110–114
Valproate in the treatment of temper outbursts [letter]. Giakas, Dec 525
Verapamil for violent patients [letter]. Greendyke, Feb 83–84
Violence by geriatric patients who need psychiatric hospitalization. Kalunian, Aug 340–343

Yohimbine
Treatment of clomipramine-induced anorgasmia with yohimbine: a case report. Price, Jan 32–33

Zimeldine
Clinical overview of serotonin reuptake inhibitors. Rickels, Dec suppl B 9–12

Journal of Clinical Psychiatry

Author Index to Volume 51: January 1990 Through December 1990

Adam B. Review of Barker P: *Basic Child Psychiatry, 5th Ed.* Jan 41
Agras WS. Treatment of social phobias. Oct suppl 52–55
Agras WS see Hewlett WA
Akiskal HS see Haykal RF
Alarcon RD. Review of Davison K, Kerr A (eds): *Contemporary Themes in Psychiatry: A Tribute to Sir Martin Roth.* Nov 488
Alarcon RD. Review of Marsella AJ, Hirschfeld RMA, Katz MM (eds): *The Measurement of Depression.* Feb 87
Alarcon RD. Review of Robins LN, Barrett JE (eds): *The Validity of Psychiatric Diagnosis.* Apr 170–171
Albert MS see Jenike MA
Albrecht H. Review of Frank BD, Kluft RP (eds): *Treatment of Victims of Sexual Abuse.* Jan 41
Alling W see Zung WWK
Alvine G, Black DW, Tsuang D. Case of delirium secondary to phenelzine/L-tryptophan combination [letter]. July 311
Amsterdam JD see Nierenberg AA; Schweizer E
Andrade C. Is maintenance ECT effective [letter with reply]? Nov 485–486
Andrade C, Pradhan N. Lithium therapy and prophylaxis [letter with reply]. Jan 37
Ankenman R. Treatment of psychotic symptoms in Alzheimer's patients [letter with reply]. Oct 437–438
Appleton AA see Munjack DJ
Arana GW see Austin LS
Asher R see Pollack MH
Austin LS, Arana GW, Ballenger JC. Rapid response of patients simultaneously treated with lithium and nortriptyline. Mar 124–125
Austin LS, Arana GW, Melvin JA. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. Aug 344–345
Austin LS, Lydiard RB, Fossey MD, Zealberg JJ, Laraia MT, Ballenger JC. Panic and phobic disorders in patients with obsessive compulsive disorder. Nov 456–458
Bacher NM. Clonazepam treatment of obsessive compulsive disorder [letter]. Apr 168–169
Ballenger JC see Austin LS
Ballinger BR. Carbamazepine in behaviorally disturbed primary dementia patients [letter with reply]. Dec 523–524
Balon R, Pohl R, Yeragani VK, Berchou R, Gershon S. Monosodium glutamate and tranylcypromine administration in healthy subjects. July 303–306
Baltazar PL see Munjack DJ
Bansil RK. Clonazepam and bipolar affective disorder [letter with reply]. Dec 522–523
Barklage NE see Greist JH
Barlow DH. Long-term outcome for patients with panic disorder treated with cognitive-behavioral therapy. Dec suppl A 17–23
Baudhuin M see Jefferson JW
Baxter LR. Brain imaging as a tool in establishing a theory of brain pathology in obsessive compulsive disorder. Feb suppl 22–25, Aug suppl 32–35
Baxter LR Jr, Schwartz JM, Guze BH, Bergman K, Szuba MP. PET imaging in obsessive compulsive disorder with and without depression. Apr suppl 61–69
Baxter LR Jr see Guze BH
Beasley CM Jr see McCombs JS
Beauchamp EA. Sculptor of damaged souls [letter]. June 257–258
Bennett JA see Thienhaus OJ
Berchou R see Balon R
Bergman K see Baxter LR Jr
Berkman L see Jacobs S
Berkowitz A see Swerdlow NR
Bernet W. Review of Everstine DS, Everstine L: *Sexual Trauma in Children and Adolescents: Dynamics and Treatment.* Jan 41
Bernet W. Review of Weil JL: *Instinctual Stimulation of Children: From Common Practice to Child Abuse, vols 1 and 2.* Mar 130–131
Bhatia MS. Isoniazid-induced obsessive compulsive neurosis [letter]. Sept 387
Biederman J. Diagnosis and treatment of adolescent anxiety disorders. May suppl 20–26. Correction, Oct 440
Biederman J, Faraone SV, Knee D, Munir K. Retrospective assessment of DSM-III attention deficit disorder in nonreferred individuals. Mar 102–106
Biederman J see Herman JB
Billings CK. Review of Juengst ET, Koenig BA (eds): *The Meaning of AIDS: Implications for Medical Science, Clinical Practice, and Public Health Policy.* Apr 171
Binder RL, McNiel DE. Relationship of gender to violent behavior in acutely disturbed psychiatric patients. Mar 110–114
Binder RL see Kalunian DA
Black DW see Alvine G
Blashfield RK see Thompson JW Jr
Blazer DG. Review of Bienenfeld D (ed): *Verwoerdt's Clinical Geropsychiatry, 3rd ed.* Oct 441
Blier P, de Montigny C, Chaput Y. Role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. Apr suppl 14–20
Blier P see de Montigny
Blinder BJ. Hyperamylasemia and binge-purge episodes [letter with reply]. Mar 128
Blum A. Triad of hyperthermia, increased REM sleep, and cataplexy during clozapine treatment [letter]? June 259–260
Board AW see Magurno JAJ
Bodkin JA. Emerging uses for high-potency benzodiazepines in psychotic disorders. May suppl 41–46
Bodkin JA see Cole JO
Bodourian SH see Walsh BT
Böhm C, Robinson DS, Gammans RE. Buspirone therapy for elderly patients with anxiety or depressive neurosis [letter]. July 309
Bohn PB see Munjack DJ
Boshes RA see Bresnahan DB
Boudewyns P see Hyer L
Boutros NN see Warner MD
Bowers MB Jr see Mazure CM
Boyer WF see Feighner JP; Lineberry CG
Bradley CA. Psychiatric diagnoses and chronic fatigue syndrome [letter with reply]. Feb 86
Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. June 236–238
Bresnahan DB, Pandey GN, Janicak PG, Sharma R, Boshes RA, Chang SS, Gierl BL, Davis JM. MAO inhibition and clinical response in depressed patients treated with phenelzine. Feb 47–50
Briggs NC, Jefferson JW, Koenecke FH. Tranylcypromine addiction: a case report and review. Oct 426–429
Brotman AW, McCormick S III. Role for high-dose antipsychotics. Apr 164–166
Brotman AW see Gelenberg AJ; Herman JB; McCormick S
Brown CS see Bryant SG; Sitland-Marken PA
Brown GL, Linnoila MI. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. Apr suppl 31–41
Brown GR. Review of clinical approaches to gender dysphoria. Feb 57–64
Bryant SG, Hokanson JA, Brown CS. Drug utilization review of prescribing patterns for trazodone versus amitriptyline. Sept suppl 27–29
Buckwald B see McGrath RE
Budman CL, Vandersall TA. Clonazepam treatment of acute mania in an AIDS patient [letter]. May 212
Burke J see Risse SC
Burke WM, Ravi NV, Dhopesh V, Vandegrift B, Maany I. Prolonged presence of metabolite in urine after compulsive cocaine use. Apr 145–148
Burrows GD. Managing long-term therapy for panic disorder. Nov suppl 9–12
Cabe DD see Munjack DJ
Cameron A see Svebak S
Cameron OG. Guidelines for diagnosis and treatment of depression in patients with medical illness. July suppl 49–54
Campeas RB see Fallon BA
Cardena E see Spiegel D
Carman JS see Lineberry CG
Carosella NW see Gwirtsman HE
Cassano GB see Petracca A
Catapano F, Galderisi S. Depression and cerebral stroke. Sept suppl 9–12
Chang SS see Bresnahan DB
Chaput Y see Blier P; de Montigny
Charney DS, Woods SW, Nagy LM, Southwick SM, Krystal JH, Heninger GR. Noradrenergic function in panic disorder. Dec suppl A 5–11
Charney DS see Price LH; Woods SW
Chen S see Risse SC
Chesley SF, Schatzki AD, DeUrrutia J, Greenblatt DJ, Shader RI, Miller LG. Cocaine augments peripheral benzodiazepine binding in humans. Oct 404–406
Chiles JA see Cohen S
Chouinard G see Reimherr FW
Chu C-C see Sitland-Marken PA
Claghorn JL see Cohn CK
Clary C, Mandos LA, Schweizer E. Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants. June 226–231
Clayton AH see Grieger TA
Clayton PJ. Bereavement and depression. July suppl 34–38
Clayton PJ. Comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. Nov suppl 35–39
Clower CG. Depression and organic mood disorder [letter]. Sept 387
Coffey CE see Lurie SN
Cohen BM see Vuckovic A
Cohen LS see Reiter SR
Cohen S, Chiles JA. Is relapse a justification for the use of high-dose antipsychotics [letter with reply]? Nov 486
Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, Claghorn JL, Dessain EC, Itil TM, Lautin A. Double-blind, multicenter comparison

of sertraline and amitriptyline in elderly depressed patients. Dec suppl B 28–33
Cohn CK see Reimherr FW
Cohn JB see Cohn CK
Cole JO, Bodkin JA. Antidepressant drug side effects. Jan suppl 21–26
Cole JO see Reimherr FW
Colvin R see Wilson SN
Comings BG see Comings DE
Comings DE, Comings BG. Controlled family history study of Tourette's syndrome, I: attention-deficit hyperactivity disorder and learning disorders. July 275–280
Comings DE, Comings BG. Controlled family history study of Tourette's syndrome, II: alcoholism, drug abuse, and obesity. July 281–287
Comings DE, Comings BG. Controlled family history study of Tourette's syndrome, III: affective and other disorders. July 288–291
Comings DE, Himes JA, Comings BG. Epidemiologic study of Tourette's syndrome in a single school district. Nov 463–469
Cooper R see Stoudemire A
Coplan JD, Gorman JM. Treatment of anxiety disorder in patients with mood disorders. Oct suppl 9–13
Coppen AJ. Introduction. Dec suppl B 3
Cowley DS see Jensen CF
Csernansky JG see Vinogradov S
Curlik SM see Katz IR
Dager SR, Heritch AJ. Case of bupropion-associated delirium. July 307–308
Dalack GW, Roose SP. Perspectives on the relationship between cardiovascular disease and affective disorder. July suppl 4–9
Dale JK see Kruesi MJP
Dasberg H see Braun P
Davidson JRT. Bupropion dosing recommendations [letter]. Feb 83
Davidson JRT. Continuation treatment of panic disorder with high-potency benzodiazepines. Dec suppl A 31–37
Davidson JRT. Reply to Goldberg JP: Bupropion dose, seizures, women, and age [letter]. Sept 388–389
Davis JM see Bresnahan DB
DeCaria CM see Hollander E
Deckert DW, Malone DA Jr. Treatment of psychotic symptoms in OCD patients [letter]. June 259
Delgado PL see Price LH; Woods SW
DelMedico VJ see Dilsaver SC
Deltito JA. Review of Burton SW, Akiskal HS (eds): *Dysthymic Disorder*. Sept 391
de Montigny C, Chaput Y, Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. Dec suppl B 4–8
de Montigny C see Blier P
DePaulo JR Jr see Holroyd S
Dessain EC see Cohn CK
DeUrrutia J see Chesley SF
Devanand DP, Malitz S, Sackeim HA. ECT in a patient with aortic aneurysm. June 255–256
DeVane CL see Ware MR
Devlin MJ see Walsh BT
Dhopesh V see Burke WM; Maany I; Macfadden W
Dietch JT, Fine M. Effect of nortriptyline in elderly patients with cardiac conduction disease. Feb 65–67
Dilsaver SC. Onset of winter depression earlier than generally thought [letter]? June 258
Dilsaver SC, DelMedico VJ, Quadri AB. Lithium-induced worsening of wintertime depression in a bipolar patient [letter]. Aug 347–348
Dilsaver SC, Jaeckle RS. Winter depression responds to an open trial of tranylcypromine. Aug 326–329
Dimitriou E. Discussant presentation: serotonin partial agonists in the treatment of depression. Sept suppl 65–66
Dhopesh V see Maany I
Dorer DJ see Gelenberg AJ
Dos Santos E. Review of Benedek EP, Cornell DG (eds): *Juvenile Homicide*. May 216
Dubin WR see Lazarus A; Roemer RA
Dubovsky SL. Generalized anxiety disorder: new concepts and psychopharmacologic therapies. Jan suppl 3–10
Dubovsky SL. Understanding and treating depression in anxious patients. Oct suppl 3–8
Dudley RG Jr. Introduction. Serotonin partial agonists in the treatment of anxiety and depression. Sept suppl 30
Dufton BD. Depression and the mediation of chronic pain. June 248–250
DuPont RL. Thinking about stopping treatment for panic disorder. Dec suppl A 38–45
Egan TM see Hamann G
Eisen JL see Rasmussen SA
Ellison JM, Gelwan E, Ogletree J. Complex partial seizure symptoms affected by marijuana abuse [letter]. Oct 439–440
Ellison JM, Milofsky JE, Ely E. Fluoxetine–induced bradycardia and syncope in two patients. Sept 385–386
Ely E see Ellison JM
Ennis J see Levitt AJ
Everett HC. Serotonergic activity and hostility [letter with reply]. Oct 438–439
Fabian C see Strand M
Fabre LF. Buspirone in the management of major depression: a placebo-controlled comparison. Sept suppl 55–61
Fabre LF. Trazodone dosing regimen: experience with single daily administration. Sept suppl 23–26
Fabre LF see Cohn CK
Fairbanks J see Fallon BA
Falk WE see Gelenberg AJ; Herman JB
Fallon BA, Liebowitz MR, Hollander E, Schneier FR, Campeas RB, Fairbanks J, Papp LA, Hatterer JA, Sandberg D. Pharmacotherapy of moral or religious scrupulosity. Dec 517–521
Faraone SV see Biederman J
Fawcett J. Targeting treatment in patients with mixed symptoms of anxiety and depression. Nov suppl 40–43
Feder R. Fluoxetine-induced mania [letter]. Dec 524–525
Feder R. Tinnitus associated with amitriptyline [letter]. Feb 85–86
Fedoroff JP see Robinson RG
Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. June 222–225
Feighner JP see Lineberry CG
Fein S, McGrath MG. Problems in diagnosing bipolar disorder in catatonic patients. May 203–205
Fine M see Dietch JT
Flint AJ. Review of Ban TA, Lehmann HE (eds): *Diagnosis and Treatment of Old Age Dementias*. Feb 88–89
Fogel BS. Major depression versus organic mood disorder: a questionable distinction. Feb 53–56
Fogel BS, Westlake R. Personality disorder diagnoses and age in inpatients with major depression. June 232–235
Forrest ARW see Harvey NS
Fossey MD see Austin LS
Fox I see Schweizer E
Frattaroli EJ. Lack of a compulsivity continuum disputed [letter with replies]. Aug 349
Friedman EH. Fluoxetine-induced akathisia in male OCD patients [letter]. May 212
Friedman EH. Fluoxetine and stuttering [letter with reply]. July 310
Friedman EH. Treatment of tardive dystonia [letter]. Aug 348
Froemming JH see Sitland-Marken PA
Frosch WA. Review of Unkefer RF (ed): *Music Therapy in the Treatment of Adults With Mental Disorders: Theoretical Bases and Clinical Interventions*. Dec 527
Furlong BG see Rosebush PI
Gainsley B see Gwirtsman HE
Galderisi S see Catapano F
Gammans RE see Böhm C
Gardner R Jr. Review of Wills C: *The Wisdom of the Genes: New Pathways in Evolution*. June 261
Gelenberg AJ. The *Journal* in focus [editorial]. Mar 94
Gelenberg AJ, Dorer DJ, Wojcik JD, Falk WE, Brotman AW, Leahy L. Crossover study of lecithin treatment of tardive dyskinesia. Apr 149–153
Gelenberg AJ see Wilson SN
Gelwan E see Ellison JM
George DT see Gwirtsman HE
Gershon S. Introduction. Insights in the use of trazodone in depressed patients. Sept suppl 4–5
Gershon S see Balon R
Giakas WJ, Seibyl JP, Mazure CM. Valproate in the treatment of temper outbursts [letter]. Dec 525
Gierl BL see Bresnahan DB
Gierz M see Swerdlow NR
Gladson M see Stoudemire A
Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. Mar 115–118
Gleason RP see Schneider LS
Goff D see Jenike MA
Gold DD. Review of Seeman MV, Greben SE (eds): *Office Treatment of Schizophrenia*. Dec 526–527
Goldberg JP. Bupropion dose, seizures, women, and age [letter with reply]. Sept 388–389
Goldberg RJ, Morris PLP, Lidofsky S. Tardive dyskinesia presenting as gastrointestinal disorder. June 253–254
Goldstein ET. Review of Havens L: *A Safe Place: Laying the Groundwork of Psychotherapy*. May 215–216
Goldstein ET. Review of Ross CA: *Multiple Personality Disorder: Diagnosis, Clinical Features, and Treatment*. July 313
Golwyn DH, Weinstock RC. MAOIs, OTC drugs, and hypertensive crisis [letter with reply]. May 213
Golwyn DH, Weinstock RC. Phenelzine treatment of elective mutism: a case report. Sept 384–385
Gonzalez-Heydrich J, Peroutka SJ. Serotonin receptor and reuptake sites: pharmacologic significance. Apr suppl 5–12
Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? Aug suppl 36–43
Goodman WK see Price LH
Gorman JM, Papp LA. Chronic anxiety: deciding the length of treatment. Jan suppl 11–15
Gorman JM see Coplan JD
Graae F. High anxiety in children. May suppl 18–19
Granacher RP Jr see Lineberry CG
Greenberg D, Witztum E, Levy A. Hoarding as a psychiatric symptom. Oct 417–421
Greenberg D see Braun P
Greenblatt DJ see Chesley SF
Greendyke RM, Webster JC, Gulya A. Verapamil for violent patients [letter]. Feb 83–84
Greist JH. Introduction. Recent advances in bipolar and obsessive compulsive disorders: nature and treatment. Aug suppl 3
Greist JH. Treating the anxiety: therapeutic options in obsessive compulsive disorder. Nov suppl 29–34
Greist JH. Treatment of obsessive compulsive disorder: psychotherapies, drugs, and other somatic treatment. Aug suppl 44–50
Greist JH, Jefferson JW, Rosenfeld R, Gutzmann LD, March JS, Barklage NE. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. July 292–297
Greist JH see March JS
Grieger TA, Clayton AH. Possible association of Ganser's syndrome and major depression [letter]. Oct 437
Grimmig J see Hamann G
Gross LS see McCombs JS
Grover GN see Schmidt PJ
Gruenberg AM see Rosenzweig MH
Grunhaus L see Guthrie S
Grunhaus LJ see Price J
Guerani G see Petracca A
Gulya A see Greendyke RM
Gunther J see Jenike MA
Guthrie S, Grunhaus L. Fluoxetine-induced stuttering [letter]. Feb 85
Guthrie S, Grunhaus L. Reply to Friedman EH: Fluoxetine and stuttering [letter]. July 310–311
Gutzmann LD see Greist JH
Guy S, Silke B. Electrocardiogram as a tool for therapeutic monitoring: a critical analysis. Dec suppl B 37–39
Guze BH, Liston EH, Baxter LR Jr. Replies to Kramer BA, Pollock VE, Schneider LS: Monitoring seizure duration during ECT [letters]. Jan 38–39
Guze BH see Baxter LR Jr; Gwirtsman HE
Gwirtsman HE, Guze BH, Yager J, Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. Sept 378–382
Gwirtsman HE, Kaye WH, George DT, Carosella NW, Jimerson DC. Replies to Blinder BJ; Larocca FEF; Walsh BT: Hyperamylasemia and binge-purge episodes [letters]. Mar 128–129
Hadigan CM see Walsh BT
Hakola HPA. Psychosocial reactions in the spouses of patients suffering polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. Jan 21–24

Hales RE see Silver JM; Yudofsky SC
Hamann G, Egan TM, Wells BG, Grimmig J. Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. Dec 502–504
Hansen F see Jacobs S
Harrison W. Replies to Golwyn DH; Magurno JAJ: MAOIs, OTC drugs, and hypertensive crisis [letters]. May 212–213
Harrison WR see Hyer L
Harto NE see Lineberry CG
Harvey NS, Summerton AM, Forrest ARW, Peet M. Compliance, the LAQ, and a new laboratory method of measuring RBC lithium [letter]. Mar 126–127
Hatterer JA see Fallon BA
Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. Nov 450–455
Hegen C see Strand M
Heiman MF. Review of Pirog-Good MA, Stets JE (eds):*Violence in Dating Relationships: Emerging Social Issues.* Mar 131–132
Heller H see Jenike MA
Heninger GR see Charney DS; Price LH; Woods SW
Heritch AJ see Dager SR
Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF. Fluoxetine-induced sexual dysfunction. Jan 25–27
Hetta J see Strand M
Hewlett WA, Vinogradov S, Agras WS. Clonazepam treatment of obsessions and compulsions. Apr 158–161
Hildebrand AM see Rosebush PI
Himes JA see Comings DE
Hindmarch I. Effects of sertraline on psychomotor performance in elderly volunteers. Dec suppl B 34–36
Hintz S, Kuck J, Peterkin JJ, Volk DM, Zisook S. Depression in the context of human immunodeficiency virus infection: implications for treatment. Dec 497–501
Hokanson JA see Bryant SG
Holland JC see Massie MJ
Hollander E, DeCaria CM, Schneier FR, Schneier HA, Liebowitz MR, Klein DF. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Mar 119–123
Hollander E see Fallon BA
Holroyd S, DePaulo JR Jr. Bipolar disorder and Crohn's disease. Oct 407–409
Hunt JI see Singh H
Huntley M. Review of Cath SH, Gurwitt A, Gunsberg L (eds): *Fathers and Their Families.* Aug 351
Hyer L, Woods MG, Summers MN, Boudewyns P, Harrison WR. Alexithymia among Vietnam veterans with posttraumatic stress disorder. June 243–247
Inglis AE see Swartz CM
Insel TR. New pharmacologic approaches to obsessive compulsive disorder. Oct suppl 47–51
Insel TR. Phenomenology of obsessive compulsive disorder. Feb suppl 4–8
Insel TR. Preface. Obsessive compulsive disorders: new perspectives. Feb suppl 3
Insel TR see Winslow JT
Irwin M see Monteiro MG
Isenberg KE. Excretion of fluoxetine in human breast milk [letter]. Apr 169
Itil TM see Cohn CK; Reimherr FW
Jacobs S, Hansen F, Kasl S, Ostfeld A, Berkman L, Kim K. Anxiety disorders during acute bereavement: risk and risk factors. July 269–274
Jacobsen FM. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. July 298–302
Jaeckle RS see Dilsaver SC
Jaffe R see Roemer RA
Jaffe RL see Lazarus A
Janicak PG see Bresnahan DB
Jarrett RB. Psychosocial aspects of depression and the role of psychotherapy. June suppl 26–35
Jatlow PI see Mazure CM
Jefferson JW. Lithium: the present and the future. Aug suppl 4–8
Jefferson JW, Baudhuin M. Reply to Andrade C: Lithium therapy and prophylaxis [letter]. Jan 37–38
Jefferson JW see Briggs NC; Greist JH; March JS
Jenike MA. Approaches to the patient with treatment-refractory obsessive compulsive disorder. Feb suppl 15–21
Jenike MA. Reply to Frattaroli EJ: Lack of a compulsivity continuum disputed [letter]. Aug 350
Jenike MA, Albert MS, Heller H, Gunther J, Goff D. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial. Jan 3–7
Jenike MA see Wilson SN
Jenkins M, Metzer WS. Avoidance of metoclopramide for the treatment of clozapine-induced nausea [letter]. May 210
Jensen CF, Cowley DS, Walker RD. Drug preferences of alcoholic polydrug abusers with and without panic. May 189–191
Jimerson DC see Gwirtsman HE
Joffe RT. Afternoon fatigue and somnolence associated with tranylcypromine treatment. May 192–193
Joffe RT see Levitt AJ
Johnston JA see Lineberry CG
Jones CL, Long CJ. Review of Brown JW (ed): *Agnosia and Apraxia: Selected Papers of Liepmann, Lange, and Potzl.* Jan 40–41
Joseph AB, O'Leary DH, Wheeler HG. Bilateral atrophy of the frontal and temporal lobes in schizophrenic patients with Capgras syndrome: a case-control study using computed tomography. Aug 322–325
Kahn D see Schneier HA
Kahn DG. Increased plasma nortriptyline concentration in a patient cotreated with fluoxetine [letter]. Jan 36
Kalayam B, Shamoian CA. Geriatric psychiatry: an update. May 177–183
Kalunian DA, Binder RL, McNiel DE. Violence by geriatric patients who need psychiatric hospitalization. Aug 340–343
Kantor SJ. Imipramine equivalents [letter with reply]. June 257
Karasu TB. Review of Amantea C: *The Lourdes of Arizona, With an Interview by R. D. Laing.* Apr 170
Kasl S see Jacobs S
Katon W, Sullivan MD. Depression and chronic medical illness. June suppl 3–11
Katon WJ. Chest pain, cardiac disease, and panic disorder. May suppl 27–30
Katz DL see Pope HG Jr
Katz IR, Simpson GM, Curlik SM, Parmelee PA, Muhly C. Pharmacologic treatment of major depression for elderly patients in residential care settings. July suppl 41–47
Kaye WH see Gwirtsman HE
Keck PE Jr see Vuckovic A
Keitner G. Review of Lefley HP, Johnson DL (eds): *Families as Allies in Treatment of the Mentally Ill.* Dec 526
Keitner GI. Review of Glick ID, Clarkin JF, Kessler DR: *Marital and Family Therapy, 3rd ed.* Sept 390
Kemph JP see Myers WC
Khanna JL. Review of Vinogradov S, Yalom ID: *A Concise Guide to Group Psychotherapy.* June 262
Khantzian EJ. Review of Chessick RD: *The Technique and Practice of Listening in Intensive Psychotherapy.* May 214
Kim K see Jacobs S
Kincare P see Mazure CM
Klein DF see Hollander E
Knee D see Biederman J
Knos G see Stoudemire A
Kobak KA see March JS
Koe BK. Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. Dec suppl B 13–17
Koenecke FH see Briggs NC
Kogan H see Silver H
Kontras SB. Review of Lask B, Fosson A: *Childhood Illness:The Psychosomatic Approach.* July 312
Korn ML see Yadalam KG
Kourany RFC. Review of Bowlby J: *A Secure Base: Parent-Child Attachment and Healthy Human Development.* Feb 89
Kramer BA, Pollock VE, Schneider LS. Monitoring seizure duration during ECT [letter with reply]. Jan 38
Kroll JL. Review of Waldinger RJ, Gunderson JG: *Effective Psychotherapy With Borderline Patients.* May 214–215
Kruesi MJP, Dale JK, Straus SE. Reply to Bradley CA: Psychiatric diagnoses and chronic fatigue syndrome [letter]. Feb 86
Krystal AD, McEvoy JP. Shared features of neuroleptic malignant syndrome and alcohol abuse complications [letter]. Dec 523
Krystal JH see Charney DS; Price LH
Kuck J see Hintz S
Kuhne AA. Review of Kulka RA, Schlenger WE, Fairbank JA, et al: *Trauma and the Vietnam War Generation: Report of Findings From the National Vietnam Veterans Readjustment Study, Vols. 1 and 2.* Nov 488–489
Kupfer DJ see Nathan RS
Kutcher SP see Levitt AJ
Lane RD. Successful fluoxetine treatment of pathologic jealousy. Aug 345–346
LaPierre YD see Reimherr FW
Laraia MT see Austin LS
Larocca FEF. Hyperamylasemia and binge-purge episodes [letter with reply]. Mar 128
Larocca FEF. Review of Andersen AE (ed): *Males With Eating Disorders.* Sept 390–391
Larocca FEF. Review of Bar-Levav R: *Thinking in the Shadow of Feelings: A New Understanding of the Hidden Forces that Shape Individuals and Societies.* May 214
Larocca FEF. Review of Ciliska D: *Beyond Dieting: Psychoeducational Interventions for Chronically Obese Women: A Non-Dieting Approach.* Dec 527
Larocca FEF. Review of Hsu LKG: *Eating Disorders.* Sept 390–391
Larocca FEF. Review of Piran N, Kaplan AS (eds): *A Day Hospital Group Treatment Program for Anorexia Nervosa and Bulimia Nervosa.* Sept 390–391
Lautin A see Cohn CK
Lazarus A, Jaffe RL, Dubin WR. Electroconvulsive therapy and major depression in Down's syndrome. Oct 422–425
Lazarus A, Rosenberg H. Treatment of rehospitalized NMS patients [letter]. Feb 84
Leahy L see Gelenberg AJ
Leckman JF see Goodman WK
Lee S. Depression in sleep apnea: a different view [letter]. July 309–310
Leeman CP. Pathophysiology of tricyclic-induced sweating [letter]. June 258–259
Lerer B see Braun P
Levander S see Svebak S
Levine SB. Review of Kaplan HS: *How to Overcome Premature Ejaculation.* Mar 130
Levine SH, Puchalski C. Pseudotumor cerebri associated with lithium therapy in two patients. June 251–253
Levitt AJ, Joffe RT, Ennis J, MacDonald C, Kutcher SP. Prevalence of cyclothymia in borderline personality disorder. Aug 335–339
Levy A see Greenberg D
Lidofsky S see Goldberg RJ
Lieb J. Antidepressant tachyphylaxis [letter]. Jan 36
Liebowitz MR see Fallon BA; Hollander E
Liljestrand A-G see Strand M
Lineberry CG, Johnston JA, Raymond RN, Samara B, Feighner JP, Harto NE, Granacher RP Jr, Weisler RH, Carman JS, Boyer WF. Fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. May 194–199
Links PS. Review of Kernberg OF, Selzer MA, Koenigsberg HW, Carr AC, Appelbaum AH: *Psychodynamic Psychotherapy of Borderline Patients.* June 261–262
Linnoila MI see Brown GL
Lipinski JF Jr, Mallya G, Zimmerman P, Pope HG Jr. Reply to Maany I: Akathisia and fluoxetine [letter]. May 210–212
Lipschutz L see Roemer RA
Liston EH see Guze BH
Lohr J see Swerdlow NR
Long CJ see Jones CL
Lopez-Ibor JJ Jr. Spectrum of mood disorders. Sept suppl 62–64
Lurie SN, Coffey CE. Caffeine-modified electroconvulsive therapy in depressed patients with medical illness. Apr 154–157
Lydiard RB see Austin LS
Maany I, Dhopesh V. Akathisia and fluoxetine [letter with reply]. May 210
Maany I see Burke WM; Macfadden W
MacDonald C see Levitt AJ
Macfadden W, Maany I, Dhopesh V, Woody G. Methadone and edema [letter]. Jan 36–37
Magruder-Habib K see Zung WWK

Magurno JAJ, Board AW. MAOIs, OTC drugs, and hypertensive crisis [letter with reply]. May 212–213
Mahadevappa H. Ganser syndrome: a case report [letter]. Apr 167
Malitz S see Devanand DP
Mallya G see Lipinski JF Jr
Malmström R see Strand M
Malone DA Jr see Deckert DW
Mandos LA see Clary C
Manschreck T see Wilson SN
March JS, Kobak KA, Jefferson JW, Mazza J, Greist JH. Double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. May 200–202
March JS see Greist JH
Margletta S see Thienhaus OJ
Marits K see Strand M
Markwalter H see Stoudemire A
Martin PR. Review of Chaudron CD, Wilkinson DA (eds): *Theories on Alcoholism.* July 312
Masco HL see Reimherr FW
Massie MJ, Holland JC. Depression and the cancer patient. July suppl 12–17
Mavissakalian M. Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia. May 184–188
Mayeux R. Depression in the patient with Parkinson's disease. July suppl 20–23
Mazure CM, Nelson JC, Jatlow PI, Kincare P, Bowers MB Jr. Relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. Aug 330–334
Mazure CM see Giakas WJ
Mazurek MF see Rosebush PI
Mazza J see March JS
McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM Jr, Gross LS. Cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a medicaid population. June suppl 60–69
McCormick S, Olin J, Brotman AW. Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. Sept 383–384
McCormick S III, Brotman AW. Reply to Cohen S: Is relapse a justification for the use of high-dose antipsychotics [letter]? Nov 486–487
McCormick S III see Brotman AW
McDougle CJ see Goodman WK
McEvoy JP see Krystal AD
McFarland BH, Miller MR, Straumfjord AA. Valproate use in the older manic patient. Nov 479–481
McGrath RE, Buckwald B, Resnick EV. Effect of L-tryptophan on seasonal affective disorder. Apr 162–163
McGrath MG see Fein S
McGraw JM. Psychology of anabolic steroid use [letter]. June 260
McNair D see Petracca A
McNiel DE see Binder RL; Kalunian DA
Melis G see Petracca A
Meller WH see Yates WR
Mellman TA, Uhde TW. Patients with frequent sleep panic: clinical findings and response to medication treatment. Dec 513–516
Meltzer-Brody S see Pollack MH
Melvin JA see Austin LS
Mendels J see Cohn CK; Reimherr FW
Menuck MN. Schizophrenic individuals with bipolar first-degree relatives [letter]. Sept 389
Merrell A see Ryken T
Metz A. Fluoxetine treatment of premenstrual syndrome [letter]. June 260
Metzer WS see Jenkins M
Miller LG see Chesley SF
Miller MR see McFarland BH
Millsap PA. Review of Andolfi M, Angelo C, De Nichilo M: *The Myth of Atlas: Families and the Therapeutic Story.* Oct 441–442
Milofsky JE see Ellison JM
Milstein KK, Milstein PS. Reverse seasonal affective disorder in major depressive disorder [letter]. Apr 167–168
Milstein PS see Milstein KK
Monteiro MG, Schuckit MA, Irwin M. Subjective feelings of anxiety in young men after ethanol and diazepam infusions. Jan 12–16
Morihisa JM. Brain-imaging approaches in psychiatry: early developmental considerations. Jan suppl 44–46
Morris PLP see Goldberg RJ; Robinson RG
Morris R see Stoudemire A
Moussong-Kovács E. Review of Dupont J (ed); Bálint M, Jackson NZ (trans): *The Clinical Diary of Sándor Ferenczi.* July 312–313
Muhly C see Katz IR
Muller KL see Schmidt PJ
Munir K see Biederman J
Munjack DJ, Baltazar PL, Bohn PB, Cabe DD, Appleton AA. Clonazepam in the treatment of social phobia: a pilot study. May suppl 35–40
Murphy DL, Pigott TA. Comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. Apr suppl 53–58
Myers WC, Kemph JP. DSM-III-R classification of murderous youth: help or hindrance? June 239–242
Nagy LM see Charney DS
Nathan RS, Perel JM, Pollock BG, Kupfer DJ. Role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. Sept 367–372
Neborsky RJ see Feighner JP
Nelson JC see Mazure CM
Nemiroff R see Swerdlow NR
Nichol MB see McCombs JS
Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. June suppl 39–47
Noyes R Jr, Perry P. Maintenance treatment with antidepressants in panic disorder. Dec suppl A 24–30
Nisita C see Petracca A
Ogletree J see Ellison JM
O'Leary DH see Joseph AB
Olin J see McCormick S
O'Neil C see Pollack MH
Ostfeld A see Jacobs S
Otto MW see Pollack MH
Ozonoff D see Wilson SN
Pandey GN see Bresnahan DB
Papp LA see Fallon BA; Gorman JM
Parmelee PA see Katz IR
Pasnau RO. Introduction. Anxiety: the burden of illness. Nov suppl 3–4
Pato C see Wilson SN
Patterson JF. Withdrawal from alprazolam dependency using clonazepam: clinical observations. May suppl 47–49
Paul SM. Introduction. Serotonin and its effects on human behavior. Apr suppl 3–4
Paulauskas S. Review of Sameroff AJ, Emde RN (eds): *Relationship Disturbances In Early Childhood: A Developmental Approach.* Mar 132
Pauls DL see Goodman WK
Peabody CA see Warner MD
Pearson HJ. Interaction of fluoxetine with carbamazepine [letter]. Mar 126
Peet M see Harvey NS
Penna MW. Review of Tardiff K: *Assessment and Management of Violent Patients.* Oct 442
Perel JM see Nathan RS
Peroutka SJ see Gonzalez-Heydrich J
Perry P see Noyes R Jr
Perry S. Combining antidepressants and psychotherapy: rationale and strategies. Jan suppl 16–20
Pesce M see Walsh BT
Peterkin JJ see Hintz S
Petracca A, Nisita C, McNair D, Melis G, Guerani G, Cassano GB. Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. Sept suppl 31–39
Phillips M. Disulfiram-induced fulminating hepatitis and monitoring guidelines [letter]. Apr 168
Pies RW. Fluoxetine treatment of premenstrual syndrome [letter]. Aug. 348
Pigott TA see Murphy DL
Pitman RK. Reply to Frattaroli EJ: Lack of a compulsivity continuum disputed [letter]. Aug 349–350
Pittard JT see Ware JC
Pohl R see Balon R
Pollack MH. Long-term management of panic disorder. May suppl 11–13
Pollack MH, Otto MW, Rosenbaum JF, Sachs GS, O'Neil C, Asher R, Meltzer-Brody S. Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic study. Dec suppl A 12–16
Pollack MH see Herman JB; Reiter SR
Pollock BG see Nathan RS
Pollock VE see Kramer BA
Pope HG Jr, Katz DL. Homicide and near-homicide by anabolic steroid users. Jan 28–31
Pope HG Jr, Yurgelun-Todd D. Schizophrenic individuals with bipolar first-degree relatives: analysis of two pedigrees. Mar 97–101
Pope HG Jr see Lipinski JF Jr
Post RM. Non-lithium treatment for bipolar disorder. Aug suppl 9–16
Pradhan N see Andrade C
Price J, Grunhaus LJ. Treatment of clomipramine-induced anorgasmia with yohimbine: a case report. Jan 32–33
Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR. Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. Apr suppl 44–50
Price LH see Goodman WK
Puchalski C see Levine SH
Pugh RL. Review of Dickstein LJ, Nadelson CC (eds): *Family Violence: Emerging Issues of a National Crisis.* Jan 40
Puzzuoli G see Schweizer E
Quadri AB see Dilsaver SC
Racy J. Professionalism: sane and insane [editorial]. Apr 138–140
Rahe RH. Psychosocial stressors and adjustment disorder: Van Gogh's life chart illustrates stress and disease. Nov suppl 13–19
Rapoport JL. Waking nightmare: an overview of obsessive compulsive disorder. Nov suppl 25–28
Raskind MA see Risse SC
Rasmussen SA, Eisen JL. Epidemiology of obsessive compulsive disorder. Feb suppl 10–13, Aug suppl 20–23
Ravi NV see Burke WM
Raymond RN see Lineberry CG
Reccoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine [letter]. Nov 487
Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels J. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled multicenter comparison study in outpatients with major depression. Dec suppl B 18–27
Reiss GR. Chronic fatigue syndrome [letter]. Apr 169
Reiter SR, Pollack MH, Rosenbaum JF, Cohen LS. Clonazepam for the treatment of social phobia. Nov 470–472
Resnick EV see McGrath RE
Rickels K. Buspirone in clinical practice. Sept suppl 51–54
Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. Dec suppl B 9–12
Rickels K see Schweizer E
Riddle MA Goodman WK
Risse SC, Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. May 206–209
Robinson DS see Böhm C
Robinson RG, Morris PLP, Fedoroff JP. Depression and cerebrovascular disease. July suppl 26–31
Roemer RA, Dubin WR, Jaffe R, Lipschutz L, Sharon D. Efficacy study of single- versus double-seizure induction with ECT in major depression. Nov 473–478
Roose SP. Introduction. Diagnosis and treatment of depression in the medical setting. July suppl 3
Roose SP see Dalack GW
Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. Sept 357–362
Rosen A see Strand M
Rosenbaum JF. Introduction. High-potency benzodiazepines: emerging uses in psychiatry. May suppl 3
Rosenbaum JF. Introduction. Panic disorder: diathesis and treatment issues. Dec suppl A 3–4
Rosenbaum JF. Summary. Dec suppl A 46
Rosenbaum JF see Herman JB; Pollack MH; Reiter SR; Weilburg JB
Rosenberg H see Lazarus A
Rosenfeld D see Schmidt PJ
Rosenfeld R see Greist JH
Rosenthal R. Review of Cussack O: *Pets and Mental Health.* Mar 131
Rosenthal RH. Review of Murphy LR, Schoenborn TF (eds): *Stress Management in Work Settings.* May 216
Rosenzweig MH, Gruenberg AM. Review of Spitzer RL, Gibbon M, Skodol AE (eds): *DSM-III-R Casebook.* Mar 130

Rubinow DR see Schmidt PJ
Rush AJ. Problems associated with the diagnosis of depression. June suppl 15–22
Ryken T, Merrell A. Haircutting and psychosis revisited [letter]. Feb 83
Sabelli HC. Anticholinergic antidepressants decrease marital hostility [letter]. Mar 127–128
Sabelli HC. Reply to Everett HC: Serotonergic activity and hostility [letter]. Oct 438–439
Sachais BA see Scharf MB
Sachs GS. Reply to Bansil RK: Clonazepam and bipolar affective disorder [letter]. Dec 522–523
Sachs GS. Use of clonazepam for bipolar affective disorder. May suppl 31–34
Sachs GS see Pollack MH
Sackeim HA see Devanand DP
Salzman C. Anxiety in the elderly: treatment strategies. Oct suppl 18–21
Salzman C. Practical considerations in the pharmacologic treatment of depression and anxiety in the elderly. Jan suppl 40–43
Salzman C. Reply to van Kempen: What are "cyclic" antidepressants [letter]? Aug 348–349
Samara B see Lineberry CG
Sandberg D see Fallon BA
Sandberg DP see Silver JM
Scharf MB. Guest editor's comments. Sept suppl 3
Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. Sept suppl 13–17
Schatzberg AF. Anxiety and adjustment disorder: a treatment approach. Nov suppl 20–24
Schatzki AD see Chesley SF
Schmidt PJ, Rosenfeld D, Muller KL, Grover GN, Rubinow DR. Case of autoimmune thyroiditis presenting as menstrual related mood disorder. Oct 434–436
Schmitz NW. Implied power of the ministry [letter]? Oct 438
Schneck JM. Edgar Allan Poe's "William Wilson" and Capgras syndrome [letter]. Sept 387–388
Schneider LS, Gleason RP. Reply to Ankenman R: Treatment of psychotic symptoms in Alzheimer's patients [letter]. Oct 437–438
Schneider LS, Gleason RP. Reply to Ballinger BR: Carbamazepine in behaviorally disturbed primary dementia patients [letter]. Dec 523–524
Schneider LS see Gleason RP; Kramer BA
Schneier FR see Fallon BA; Hollander E
Schneier HA, Kahn D. Selective response to carbamazepine in a case of organic mood disorder [letter]. Nov 485
Schneier HA see Hollander E
Schou M. Lithium treatment during pregnancy, delivery, and lactation: an update. Oct 410–413
Schuckit MA see Monteiro MG
Schwartz JM see Baxter LR Jr
Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial for fluoxetine? Jan 8–11
Schweizer E see Clary C; Rickels K
Sclar DA see McCombs JS
Scott AM. Review of Vaux A: *Social Support: Theory, Research and Intervention.* Feb 87–88
Scurfield RM see Risse SC
Seibyl JP see Giakas WJ
Shader RI see Chesley SF
Shamoian CA see Kalayam B
Sharma R see Bresnahan DB
Sharon D see Roemer RA
Shedlack KJ see Vuckovic A
Sheeley WF. Koro or hysteria [letter with reply]? Jan 39
Shrivastava R see Cohn CK
Silke B see Guy S
Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. Nov 459–462
Silver JM, Hales RE, Yudofsky SC. Psychopharmacology of depression in neurologic disorders. Jan suppl 33–39
Silver JM, Sandberg DP, Hales RE. New approaches in the pharmacotherapy of posttraumatic stress disorder. Oct suppl 33–38
Silver JM see Yudofsky SC
Silvestrini B. Paradoxical stress response: a possible common basis for depression and other conditions. Sept suppl 6–8
Simpson GM see Katz IR; Singh H; Yadalam KG
Singh H, Hunt JI, Vitiello B, Simpson GM. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Aug 319–321
Sitland-Marken PA, Wells BG, Froemming JH, Chu C-C, Brown CS. Psychiatric applications of bromocriptine therapy. Feb 68–82
Sörensen S see Strand M
Southwick SM see Charney DS
Spiegel D, Cardena E. New uses of hypnosis in the treatment of posttraumatic stress disorder. Oct suppl 39–43
Stanley B see Stanley M
Stanley M, Stanley B. Postmortem evidence for serotonin's role in suicide. Apr suppl 22–28
Stein BA. Review of Lewis JM: *The Birth of a Family: An Empirical Inquiry.* June 262
Stimmel GL see McCombs JS
Stoudemire A, Knos G, Gladson M, Markwalter H, Sung Y-F, Morris R, Cooper R. Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients. Dec 508–512
Strand M, Hetta J, Rosen A, Sörensen S, Malström R, Fabian C, Marits K, Vetterskog K, Liljestrand A-G, Hegen C. Double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. Sept suppl 40–45
Straumfjord AA see McFarland BH
Straus SE see Kruesi MJP
Sullivan MD see Katon W
Summers MN see Hyer L
Summerton AM see Harvey NS
Sung Y-F see Stoudemire A
Surawicz FG. Review of Pressman B, Cameron G, Rothery M (eds): *Intervening With Assaulted Women: Current Theory, Research, and Practice.* Oct 442
Surawicz FG. Review of Rothblum ED, Cole E (eds): *Lesbianism: Affirming Nontraditional Roles.* Nov 489
Surman OS see Wilson SN
Svebak S, Cameron A, Levander S. Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects. May suppl 14–17
Swartz CM, Inglis AE. Blood pressure reduction with ECT response. Oct 414–416
Swerdlow NR, Gierz M, Berkowitz A, Nemiroff R, Lohr J. Electroconvulsive therapy in a patient with severe tic and major depressive episode. Jan 34–35
Szuba MP see Baxter LR Jr
Tanay E. Review of Roth N: *The Psychiatry of Writing a Will.* Aug 351
Taylor SE see Wise MG
Tesar GE. High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience. May suppl 4–10
Thaggard SL. Review of Hughes S: *Ryan: A Mother's Story of Her Hyperactive/Tourette Syndrome Child.* Nov 489
Thase ME. Relapse and recurrence in unipolar major depression: short-term and long-term approaches. June suppl 51–57
Thienhaus OJ. Reply to Andrade C: Is maintenance ECT effective [letter]? Nov 485–486
Thienhaus OJ, Margletta S, Bennett JA. Study of the clinical efficacy of maintenance ECT. Apr 141–144
Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic meation and priapism: a comprehensive review. Oct 430–433
Trimble MR. Worldwide use of clomipramine. Aug suppl 51–54
Tsuang D see Alvine G
Tyler DL see Feighner JP
Udelman DL see Udelman HD
Udelman HD, Udelman DL. Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. Sept suppl 46–50
Uhde TW see Mellman TA
Vandegrift B see Burke WM
Vandersall TA see Budman CL
van Kempen GMJ. What are "cyclic" antidepressants [letter with reply]? Aug 348–349
Velez R see Zung WWK
Vetterskog K see Strand M
Vinogradov S, Csernansky JG. Postpartum psychosis with abnormal movements: dopamine supersensitivity unmasked by withdrawal of endogenous estrogens? Sept 365–366
Vinogradov S see Hewlett WA
Vitiello B see Singh H
Volk DM see Hintz S
Vuckovic A, Cohen BM, Keck PE Jr, Shedlack KJ. Neuroleptic dosage regimens in psychotic inpatients: a retrospective comparison. Mar 107–109
Walker RD see Jensen CF
Walsh AC. Anticoagulant therapy for dementia [letter]. Dec 522
Walsh BT, Devlin MJ, Pesce M, Wong LM, Hadigan CM. Hyperamylasemia and binge-purge episodes [letter with reply]. Mar 128–129
Walsh BT, Wong LM, Pesce MA, Hadigan CM, Bodourian SH. Hyperamylasemia in bulimia nervosa. Sept 373–377
Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. Sept suppl 18–22
Ware MR, DeVane CL. Imipramine treatment of panic disorder during pregnancy. Nov 482–484
Ware MR see Reccoppa L; Thompson JW Jr
Warner MD, Boutros NN, Peabody CA. Usefulness of screening EEGs in a psychiatric inpatient population. Sept 363–364
Webster JC see Greendyke RM
Weddington WW. Prolonged detection period for cocaine and metabolite [letter]. Aug 347
Weilburg JB, Rosenbaum JF. Reply to Kantor SJ: Imipramine equivalents [letter]. June 257
Weinstock RC see Golwyn DH
Weise C see Schweizer E
Weisler RH see Lineberry CG
Weissman MM. Hidden patient: unrecognized panic disorder. Nov suppl 5–8
Welch WA see Reccoppa L
Wells BG see Hamann G; Sitland-Marken PA
Westermeyer J. Reply to Sheeley WF: Koro or hysteria [letter]? Jan 39
Westlake R see Fogel BS
Wheeler HG see Joseph AB
Whitters A see Risse SC
Wilson SN, Surman OS, Colvin R, Ozonoff D, Gelenberg AJ, Jenike MA, Manschreck T, Pato C. Unusual lymphocyte subset distribution in some depressed patients. Feb 51–52
Winslow JT, Insel TR. Neurobiology of obsessive compulsive disorder: a possible role for serotonin. Aug suppl 27–31
Wise MG, Taylor SE. Anxiety and mood disorders in medically ill patients. Jan suppl 27–32
Witztum E see Greenberg D
Wojcik JD see Gelenberg AJ
Wong LM see Walsh BT
Woods MG see Hyer L
Woods SW, Charney DS, Delgado PL, Heninger GR. Effect of long-term imipramine treatment on carbon dioxide-induced anxiety in panic disorder patients. Dec 505–507
Woods SW see Charney DS; Price LH
Woody G see Macfadden W
Yadalam KG, Korn ML, Simpson GM. Tardive dystonia: four case histories. Jan 17–20
Yager J see Gwirtsman HE
Yates WR, Meller WH. Panic disorder and cocaine abuse in alcoholics [letter]. Oct 440
Yeragani VK see Balon R
Yudofsky SC, Silver JM, Hales RE. Pharmacologic management of aggression in the elderly. Oct suppl 22–28
Yudofsky SC see Silver JM
Yurgelun-Todd D see Pope HG Jr
Zealoerg JJ see Austin LS
Zimmerman P see Lipinski JF Jr
Zisook S see Hintz S
Zlotogorski D see Silver H
Zung WWK. Role of rating scales in the identification and management of the depressed patient in the primary care setting. June suppl 72–76
Zung WWK, Magruder-Habib K, Velez R, Alling W. Comorbidity of anxiety and depression in general medical patients: a longitudinal study. June suppl 77–80